Technology: The application of scientific knowledge to practical purposes in any field. It includes methods, techniques, and instrumentation.Cancer Vaccines: Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.Vaccination: Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Vaccines: Suspensions of killed or attenuated microorganisms (bacteria, viruses, fungi, protozoa), antigenic proteins, synthetic constructs, or other bio-molecular derivatives, administered for the prevention, amelioration, or treatment of infectious and other diseases.Biological Markers: Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, environmental exposure and its effects, disease diagnosis, metabolic processes, substance abuse, pregnancy, cell line development, epidemiologic studies, etc.Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Mice, Inbred BALB CAntigens: Substances that are recognized by the immune system and induce an immune reaction.T-Lymphocytes, Cytotoxic: Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.Immunotherapy: Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.Bibliometrics: The use of statistical methods in the analysis of a body of literature to reveal the historical development of subject fields and patterns of authorship, publication, and use. Formerly called statistical bibliography. (from The ALA Glossary of Library and Information Science, 1983)Glycogen Storage Disease Type V: Glycogenosis due to muscle phosphorylase deficiency. Characterized by painful cramps following sustained exercise.Vaccines, Inactivated: Vaccines in which the infectious microbial nucleic acid components have been destroyed by chemical or physical treatment (e.g., formalin, beta-propiolactone, gamma radiation) without affecting the antigenicity or immunogenicity of the viral coat or bacterial outer membrane proteins.Viral Vaccines: Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease.Vaccines, DNA: Recombinant DNA vectors encoding antigens administered for the prevention or treatment of disease. The host cells take up the DNA, express the antigen, and present it to the immune system in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigens. The vector is called naked DNA because there is no need for complex formulations or delivery agents; the plasmid is injected in saline or other buffers.Periodicals as Topic: A publication issued at stated, more or less regular, intervals.Manuscripts as Topic: Compositions written by hand, as one written before the invention or adoption of printing. A manuscript may also refer to a handwritten copy of an ancient author. A manuscript may be handwritten or typewritten as distinguished from a printed copy, especially the copy of a writer's work from which printed copies are made. (Webster, 3d ed)Biofuels: Hydrocarbon-rich byproducts from the non-fossilized BIOMASS that are combusted to generate energy as opposed to fossilized hydrocarbon deposits (FOSSIL FUELS).Federal Government: The level of governmental organization and function at the national or country-wide level.Biological Science Disciplines: All of the divisions of the natural sciences dealing with the various aspects of the phenomena of life and vital processes. The concept includes anatomy and physiology, biochemistry and biophysics, and the biology of animals, plants, and microorganisms. It should be differentiated from BIOLOGY, one of its subdivisions, concerned specifically with the origin and life processes of living organisms.Science: The study of natural phenomena by observation, measurement, and experimentation.Influenza Vaccines: Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The vaccine is usually bivalent or trivalent, containing one or two INFLUENZAVIRUS A strains and one INFLUENZAVIRUS B strain.United StatesMiniaturization: The design or construction of objects greatly reduced in scale.Automatic Data Processing: Data processing largely performed by automatic means.Quantum Theory: The theory that the radiation and absorption of energy take place in definite quantities called quanta (E) which vary in size and are defined by the equation E=hv in which h is Planck's constant and v is the frequency of the radiation.Organ Preservation Solutions: Solutions used to store organs and minimize tissue damage, particularly while awaiting implantation.Memory, Short-Term: Remembrance of information for a few seconds to hours.Tissue Preservation: The process by which a tissue or aggregate of cells is kept alive outside of the organism from which it was derived (i.e., kept from decay by means of a chemical agent, cooling, or a fluid substitute that mimics the natural state within the organism).Eye Banks: Centers for storing various parts of the eye for future use.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Prostatic Neoplasms: Tumors or cancer of the PROSTATE.Vaccines, Synthetic: Small synthetic peptides that mimic surface antigens of pathogens and are immunogenic, or vaccines manufactured with the aid of recombinant DNA techniques. The latter vaccines may also be whole viruses whose nucleic acids have been modified.Vaccines, Subunit: Vaccines consisting of one or more antigens that stimulate a strong immune response. They are purified from microorganisms or produced by recombinant DNA techniques, or they can be chemically synthesized peptides.Vaccines, Combined: Two or more vaccines in a single dosage form.Bacterial Vaccines: Suspensions of attenuated or killed bacteria administered for the prevention or treatment of infectious bacterial disease.Marketing: Activity involved in transfer of goods from producer to consumer or in the exchange of services.Longitudinal Studies: Studies in which variables relating to an individual or group of individuals are assessed over a period of time.Meningococcal Vaccines: Vaccines or candidate vaccines used to prevent infection with NEISSERIA MENINGITIDIS.QuinazolinesDrug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Newspapers: Publications printed and distributed daily, weekly, or at some other regular and usually short interval, containing news, articles of opinion (as editorials and letters), features, advertising, and announcements of current interest. (Webster's 3d ed)Molluginaceae: A plant family of the order Caryophyllales, subclass Caryophyllidae, class Magnoliopsida. Some members contain triterpenoid saponins.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Genetic Vectors: DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition.Gene Transfer Techniques: The introduction of functional (usually cloned) GENES into cells. A variety of techniques and naturally occurring processes are used for the gene transfer such as cell hybridization, LIPOSOMES or microcell-mediated gene transfer, ELECTROPORATION, chromosome-mediated gene transfer, TRANSFECTION, and GENETIC TRANSDUCTION. Gene transfer may result in genetically transformed cells and individual organisms.Retroviridae: Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).Cell Line, Tumor: A cell line derived from cultured tumor cells.Cell Line: Established cell cultures that have the potential to propagate indefinitely.

Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. (1/3029)

Interleukin-12 (IL-12) is a potent antitumor cytokine, which induces and enhances the activity of natural killer (NK) cells, lymphokine activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). IL-12 also stimulates IFN-gamma production from both T cells and NK cells. In this study, we transfected methylcholanthrene-induced fibrosarcoma (MCA-D) with TNF gene and investigated the therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect is enhanced by systemic administration of recombinant IL-12 (rIL-12), in a murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL-12 showed slight or moderate inhibition of pre-established tumor. However, simultaneous application of the vaccine and rIL-12 resulted in complete eradication. The cytotoxicity of CTL against parental tumor cells was enhanced with the combination of the vaccine and rIL-12, and IFN-gamma production from spleen cells also increased synergistically. Our findings show that synergistic enhancement of CTL activity and IFN-gamma production could play an important role in the antitumor effect of combination therapy using TNF gene-transduced cancer vaccine and rIL-12.  (+info)

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. (2/3029)

The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an antitumor T-cell response. Here, we demonstrate that functional DCs can be generated from peripheral blood of patients with metastatic renal cell carcinoma (RCC) by culture of monocytes/macrophages (CD14+) in autologous serum containing medium (RPMI) in the presence of granulocyte macrophage colony-stimulating factor and interleukin (IL) 4. For testing the capability of RCC-antigen uptake and processing, we loaded these DCs with autologous tumor lysate (TuLy) using liposomes, after which cytometric analysis of the DCs revealed a markedly increased expression of HLA class I antigen and a persistent high expression of class II. The immunogenicity of DC-TuLy was further tested in cultures of renal tumor infiltrating lymphocytes (TILs) cultured in low-dose IL-2 (20 Biologic Response Modifier Program units/ml). A synergistic effect of DC-TuLy and IL-2 in stimulating a T cell-dependent immune response was demonstrated by: (a) the increase of growth expansion of TILs (9.4-14.3-fold; day 21); (b) the up-regulation of the CD3+ CD56- TcR+ (both CD4+ and CD8+) cell population; (c) the augmentation of T cell-restricted autologous tumor lysis; and (d) the enhancement of IFN-gamma, tumor necrosis factor-alpha, granulocyte macrophage colony-stimulating factor, and IL-6 mRNA expression by TILs. Taken together, these data implicate that DC-TuLy can activate immunosuppressed TIL via an induction of enhanced antitumor CTL responses associated with production of Thl cells. This indicates a potential role of DC-TuLy vaccines for induction of active immunity in patients with advanced RCC.  (+info)

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. (3/3029)

In this study we used TEPITOPE, a new epitope prediction software, to identify sequence segments on the MAGE-3 protein with promiscuous binding to histocompatibility leukocyte antigen (HLA)-DR molecules. Synthetic peptides corresponding to the identified sequences were synthesized and used to propagate CD4(+) T cells from the blood of a healthy donor. CD4(+) T cells strongly recognized MAGE-3281-295 and, to a lesser extent, MAGE-3141-155 and MAGE-3146-160. Moreover, CD4(+) T cells proliferated in the presence of recombinant MAGE-3 after processing and presentation by autologous antigen presenting cells, demonstrating that the MAGE-3 epitopes recognized are naturally processed. CD4(+) T cells, mostly of the T helper 1 type, showed specific lytic activity against HLA-DR11/MAGE-3-positive melanoma cells. Cold target inhibition experiments demonstrated indeed that the CD4(+) T cells recognized MAGE-3281-295 in association with HLA-DR11 on melanoma cells. This is the first evidence that a tumor-specific shared antigen forms CD4(+) T cell epitopes. Furthermore, we validated the use of algorithms for the prediction of promiscuous CD4(+) T cell epitopes, thus opening the possibility of wide application to other tumor-associated antigens. These results have direct implications for cancer immunotherapy in the design of peptide-based vaccines with tumor-specific CD4(+) T cell epitopes.  (+info)

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. (4/3029)

We have reported previously that murine bone marrow-derived dendritic cells (DC) pulsed with whole tumor lysates can mediate potent antitumor immune responses both in vitro and in vivo. Because successful therapy was dependent on host immune T cells, we have now evaluated whether the systemic administration of the T cell stimulatory/growth promoting cytokine interleukin-2 (IL-2) could enhance tumor lysate-pulsed DC-based immunizations to further promote protective immunity toward, and therapeutic rejection of, syngeneic murine tumors. In three separate approaches using a weakly immunogenic sarcoma (MCA-207), the systemic administration of nontoxic doses of recombinant IL-2 (20,000 and 40,000 IU/dose) was capable of mediating significant increases in the potency of DC-based immunizations. IL-2 could augment the efficacy of tumor lysate-pulsed DC to induce protective immunity to lethal tumor challenge as well as enhance splenic cytotoxic T lymphocyte activity and interferon-gamma production in these treated mice. Moreover, treatment with the combination of tumor lysate-pulsed DC and IL-2 could also mediate regressions of established pulmonary 3-day micrometastases and 7-day macrometastases as well as established 14- and 28-day s.c. tumors, leading to either significant cure rates or prolongation in overall survival. Collectively, these findings show that nontoxic doses of recombinant IL-2 can potentiate the antitumor effects of tumor lysate-pulsed DC in vivo and provide preclinical rationale for the use of IL-2 in DC-based vaccine strategies in patients with advanced cancer.  (+info)

Cytokine-based tumor cell vaccine is equally effective against parental and isogenic multidrug-resistant myeloma cells: the role of cytotoxic T lymphocytes. (5/3029)

Tumor cells that survive initial courses of chemotherapy may do so by acquiring a multidrug-resistant phenotype. This particular mechanism of drug resistance may also confer resistance to physiological effectors of apoptosis that could potentially reduce the efficacy of immune therapies that use these pathways of cell death. We have previously demonstrated high efficacy for a cytokine-based tumor cell vaccine in a murine MPC11 myeloma model. In the present study, the effects of this vaccination were compared in MPC11 cells and their isogenic sublines selected for mdr1/P-glycoprotein (Pgp)-mediated multidrug resistance (MDR). Immunization with MPC11 cells expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-12 (IL-12) led to long-lasting protection of mice against subcutaneous (sc) challenge with both parental cells or their MDR variants. Similarly, immunization with GM-CSF/IL-12-transfected MDR sublines caused rejection of transplantation of both parental cells and the MDR sublines. Whereas MPC11 cells and their MDR variants were resistant to APO-1/CD95/Fas ligand, the immunization generated potent granzyme B/perforin-secreting cytotoxic T lymphocytes (CTLs) that were similarly effective against both parental and isogenic MDR cells. We conclude that MDR mediated by mdr1/Pgp did not interfere with lysis by pore-forming CTLs. Immunotherapy based on pore-forming CTLs may be an attractive approach to the treatment of drug-resistant myeloma.  (+info)

Cancer vaccines. (6/3029)

It has been more than 100 years since the first reported attempts to activate a patient's immune system to eradicate developing cancers. Although a few of the subsequent vaccine studies demonstrated clinically significant treatment effects, active immunotherapy has not yet become an established cancer treatment modality. Two recent advances have allowed the design of more specific cancer vaccine approaches: improved molecular biology techniques and a greater understanding of the mechanisms involved in the activation of T cells. These advances have resulted in improved systemic antitumor immune responses in animal models. Because most tumor antigens recognized by T cells are still not known, the tumor cell itself is the best source of immunizing antigens. For this reason, most vaccine approaches currently being tested in the clinics use whole cancer cells that have been genetically modified to express genes that are now known to be critical mediators of immune system activation. In the future, the molecular definition of tumor-specific antigens that are recognized by activated T cells will allow the development of targeted antigen-specific vaccines for the treatment of patients with cancer.  (+info)

Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. (7/3029)

Many human and mouse tumor antigens are normal, nonmutated tissue differentiation antigens. Consequently, immunization with these "self" antigens could induce autoimmunity. When we tried to induce immune responses to five mouse melanocyte differentiation antigens, gp100, MART-1, tyrosinase, and tyrosinase-related proteins (TRP) 1 and TRP-2, we observed striking depigmentation and melanocyte destruction only in the skin of mice inoculated with a vaccinia virus encoding mouse TRP-1. These mice rejected a lethal challenge of B16 melanoma, indicating the immune response against TRP-1 could destroy both normal and malignant melanocytes. Cytotoxic T lymphocytes specific for TRP-1 could not be detected in depigmented mice, but high titers of IgG anti-TRP-1 antibodies were present. Experiments with knockout mice revealed an absolute dependence on major histocompatibility complex class II, but not major histocompatibility complex class I, for the induction of both vitiligo and tumor protection. Together, these results suggest that the deliberate induction of self-reactivity using a recombinant viral vector can lead to tumor destruction, and that in this model, CD4(+) T lymphocytes are an integral part of this process. Vaccine strategies targeting tissue differentiation antigens may be valuable in cancers arising from nonessential cells and organs such as melanocytes, prostate, testis, breast, and ovary.  (+info)

Preclinical development of human granulocyte-macrophage colony-stimulating factor-transfected melanoma cell vaccine using established canine cell lines and normal dogs. (8/3029)

Tumor vaccines and gene therapy have received significant attention as means of increasing cellular and humoral immune responses to cancer. We conducted a pilot study of seven research dogs to determine whether intradermal injection of canine tumor cells transfected via the Accell particle-mediated gene transfer device with the cDNA for human granulocyte-macrophage colony-stimulating factor (hGM-CSF) would generate biologically relevant levels of protein and result in demonstrable histological changes at sites of vaccination. Tumor cell vaccines of 10(7) irradiated canine melanoma cells were nontoxic, safe, and well tolerated. No significant alterations in blood chemistry values or hematological profiles were detected. A histological review of control vaccine sites revealed inflammatory responses predominated by eosinophils, whereas vaccine sites with hGM-CSF-transfected tumor cells had an influx of neutrophils and macrophages. Enzyme-linked immunosorbent assays of skin biopsies from vaccine sites had local hGM-CSF production (8.68-16.82 ng/site of injection) at 24 hours after injection and detectable levels (0.014-0.081 ng/site) for < or =2 weeks following vaccination. Flow cytometric analysis of hGM-CSF-transfected cells demonstrated < or =25% transfection efficiency, and hGM-CSF levels obtained during time-course assays demonstrated biologically relevant levels for both irradiated and nonirradiated samples. These data demonstrate the in vivo biological activity of irradiated hGM-CSF-transfected canine tumor cells and help provide evidence for a valid translational research model of spontaneous tumors.  (+info)

*Cancer vaccine

A cancer vaccine is a vaccine that either treats existing cancer or prevents development of a cancer. Vaccines that treat ... "Oral vaccine could fight source of stomach cancers". Vaccine News Reports. Giarelli E (2007). "Cancer vaccines: a new frontier ... Some types of cancer, such as cervical cancer and some liver cancers, are caused by viruses (oncoviruses). Traditional vaccines ... such as HPV vaccine and hepatitis B vaccine, prevent those types of cancer. These vaccines are not further discussed in this ...

*Lung cancer vaccine

... may refer to: A cancer vaccine for lung cancer: CimaVax-EGF, the first therapeutic cancer vaccine developed ... to target lung cancer. Stimuvax, which had promising results from a phase IIB trial for inoperable lung cancer.. ...

*Dendritic cells- based cancer vaccines

"Therapeutic Cancer Vaccines: Past, Present and Future". Advances in cancer research. 119: 421-475. doi:10.1016/B978-0-12-407190 ... based cancer vaccine for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (CRPC ... DC vaccine has been introduced as a new therapeutic strategy in cancer patients. DC-based immunotherapy is safe and can promote ... Palucka, Karolina; Banchereau, Jacques (2013-07-25). "Dendritic cell-based cancer therapeutic vaccines". Immunity. 39 (1): 38- ...

*Keyhole limpet hemocyanin

... for cancer and the documented efficacy of KLH as a superior carrier protein for cancer vaccines are creating a significant ... "Cancer Vaccines". "Keyhole Limpet Hemocyanin Knowledge Base". Harris JR, Markl J (1999). "Keyhole limpet hemocyanin (KLH): a ... KLH is being tested in a variety of cancer vaccines, including non-Hodgkins lymphoma, cutaneous melanoma, breast and bladder ... cancer. These vaccines contain specific tumor-associated antigens conjugated to KLH to stimulate anti-tumor immune responses ...

*Cervarix

"Who invented the VLP cervical cancer vaccines?". J Natl Cancer Inst. 98 (7): 433. doi:10.1093/jnci/djj144. PMID 16595773. ... Cervarix is a vaccine against certain types of cancer-causing human papillomavirus (HPV). Cervarix is designed to prevent ... "Vaccine vs cervical cancer virus launched in Manila". GMA Network. Associated Press. 25 August 2007. "Glaxo prepares to launch ... "New data show Cervarix, GSK'S HPV 16/18 cervical cancer candidate vaccine, is highly immunogenic and well-tolerated in women ...

*Dmitry Gabrilovich

"Prof Dmitry Gabrilovich". Cancer Vaccine Institute. Retrieved 17 February 2014. "Dmitry I. Gabrilovich, M.D., Ph.D". The Wistar ... Nat Rev Cancer. 2013 Oct;13(10):739-52. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, Villagra A, Antonia S, ... The Gabrilovich lab focuses on immature myeloid cell biology and its relation to cancer. These cells have been linked to a ... Prior to joining The Wistar Institute, Gabrilovich was a senior member at the Moffitt Cancer Center in Tampa. Condamine T, ...

*Julianna Lisziewicz

"Treos Bio Limited , Cancer Vaccine Technology". treosbio.com. Retrieved 2017-11-29. Holt, Nathalia (2014). Cured : How the ... PolyPEPI™ immunotherapies to treat lung cancer, breast cancer, and colorectal cancer were created using the computational ... TREOS Bio is a company that develops precision vaccines to treat and prevent cancer using computational immune-oncology. TREOS ... This vaccine has been clinically proven, and it opens the door for more new dendritic cell-targeting vaccines to be created for ...

*St Monica's High School

"Catholic school bans girls from having cervical cancer jabs". The Daily Telegraph. London. "School refuses 'cancer vaccine'". ... the school came to the attention of the national media after it banned female pupils from receiving the cervical cancer HPV ...

*Aliasger K. Salem

Researchers Aim to Develop Cancer Vaccines , News , Drug Discovery and Development Magazine "Nanoparticles in Vaccine Delivery ... and the Holden Comprehensive Cancer Center. Salem was an American Cancer Society Research Scholar from 2009 to 2013. Salem is ... About Holden Pharmacy researcher to use American Cancer Society grant for melanoma research Cancer Signaling and Experimental ... "Peer Review Committee for Cancer Drug Discovery (CDD)". cancer.org. Teaching award-winner Salem encourages active learning , ...

*Jonathan Lewis (oncologist)

... the biology and treatment of pancreatic cancer, molecular cancer vaccines, gene therapy and the translation of laboratory ... "A New Generation of Cancer Vaccines - New York Times". Nytimes.com. Retrieved 2014-03-01. Lewis JJ (October 2004). "Therapeutic ... and the potential use of vaccines in pancreatic cancer. Lewis has authored over 200 scientific publications, which include work ... cancer vaccines: using unique antigens". Proceedings of the National Academy of Sciences of the United States of America. 101 ...

*Galena Biopharma

Donnelly, Julie M. (June 6, 2011). "RXi advances breast cancer vaccine". Boston Business Journal. Retrieved 1 April 2012. Lang ... The acquisition included the breast cancer drug NeuVax. In June 2011, NeuVax was approved by the United States Food and Drug ... Galena acquired the experimental breast cancer drug NeuVax in 2011 and are currently in phase II trials to combine the drug ... GALE-301 and GALE-302 are immunotherapies in phase I and II trials for ovarian and breast cancers. Siemers, Erik; Michelle Lang ...

*Anti-austerity movement in Ireland

"Real cost of cancer vaccine cuts". The Irish Times. 8 November 2008. Retrieved 7 January 2009. "Govt lambasted for scrapping ... "8,000 back cancer vaccine on Facebook". Irish Examiner. 24 November 2008. Archived from the original on 5 March 2009. Retrieved ... "Debate on Cervical Cancer Vaccine". Damien Blake. 13 November 2008. Archived from the original on 7 January 2009. Retrieved 7 ... "McDaid refuses to back Government on cancer vaccine vote". The Irish Times. 13 November 2008. Retrieved 7 January 2009. " ...

*Fallout of the 2009 Irish government budget

"Real cost of cancer vaccine cuts". The Irish Times. 8 November 2008. Retrieved 7 January 2009. "Govt lambasted for scrapping ... "8,000 back cancer vaccine on Facebook". Irish Examiner. 24 November 2008. Archived from the original on 5 March 2009. Retrieved ... "Debate on Cervical Cancer Vaccine". Damien Blake. 13 November 2008. Archived from the original on 23 December 2008. Retrieved 7 ... There was a public backlash, with a "Harney must reinstate cervical cancer vaccine" protest Facebook attracting 8,000 members ...

*Oncophage

... also known as cancer vaccine heat shock protein peptide complex-96 and cancer vaccine HSPPC-96, is a personalized cancer ... Oncophage is one of a group of new drugs called cancer vaccines that intend to train the body's immune system to fight the ... Itoh K, Yamada A, Mine T, Noguchi M (February 2009). "Recent advances in cancer vaccines: an overview". Jpn. J. Clin. Oncol. 39 ... While chemotherapy is often accompanied by severe side effects, cancer vaccines tend to have only minimal ones (often only ...

*Jim McDaid

"McDaid unrepentant over cancer vaccine vote". Irish Independent. 14 November 2008. "Jim McDaid says he will not give up pension ... This threat was followed through in November 2008 when he abstained from a vote on the Cervical cancer vaccination programme, ...

*Aidan McGrath

"Young Councillors welcome cervical cancer vaccine". Archived from the original on 4 November 2011. "Another Outstanding ... TD and former Minister for Health in an effort to have the cervical cancer vaccine made available free of charge for all 12-18- ...

*Minigene

"A novel minigene scaffold for therapeutic cancer vaccines". Oncoimmunology. 3 (1): e27529. doi:10.4161/onci.27529. PMID ... Cancer is a complex, heterogeneous disease that can be hereditary or the result of environmental stimuli. Minigenes are used to ... Additionally, the prospect of using minigenes as a cancer immunotherapy is being explored. Recombinant DNA RNA Splicing Exon ... Minigenes help researchers identify genetic mutations in cancer that result in splicing errors and determine the downstream ...

*Kunjin virus

This research may lead to vaccines for cancer and HIV. "Department of Health and Ageing-Kunjin virus infection-Fact Sheet". ... "Australian virus may lead to cancer vaccine". Australian Broadcasting Corporation. 2005-03-31. Retrieved 2009-08-08. "New ... There is no available vaccine against Kunjin virus. In 2005, scientists at the Queensland Institute of Medical Research and the ... ISBN 0-8138-0379-9. Bhattacharya, Shaoni (2003-08-12). "West Nile Virus's milder cousin gives vaccine hope". New Scientist. ...

*Ensituximab

"From Vaccines To Monoclonal Antibodies: Creating Milestones In Cancer Theranostics". Frost & Sullivan. 14 September 2007. Staff ... Morrison, Trista (July 11, 2007). "Neogenix Uses Cancer Vaccine And Antibody Approaches". BioWorld Today. Neogenix Oncology, ... Results from a small Phase II trial in people with pancreatic or colon cancer presented in 2012 were not promising with regard ... In 2016, Precision released data from a Phase II trial colorectal cancer and at that time was working with Cytovance Biologics ...

*The Compatibility Gene

Website Telegraph: Davis comments on 'Cancer vaccine'. ... last are elements of the immune system which recognise cancer ...

*Gavi, the Vaccine Alliance

... the Vaccine Alliance. Boseley, Sarah (2011-11-17). "Green light from Gavi for cervical cancer vaccine". Guardian. Retrieved ... Gavi, the Vaccine Alliance (Gavi for short; previously the GAVI Alliance, and before that the Global Alliance for Vaccines and ... The new funds will support the work of the GAVI Alliance (formerly the Global Alliance for Vaccines and Immunization) Lesaar, ... Originally it was the Global Alliance for Vaccines and Immunisations, then most recently the GAVI Alliance, and now Gavi, ...

*Timeline of global health

Boseley, Sarah (2011-11-17). "Green light from Gavi for cervical cancer vaccine". Guardian. Retrieved 2014-04-29. 25 January ... Offit, Paul A. (2007). The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis. Yale ... Antitoxins and vaccines for numerous diseases including cholera and tuberculosis are developed during this period, building on ... "Salk produces polio vaccine". PBS. Retrieved June 14, 2016. "History of Salk: About Salk". Retrieved June 14, 2016. ...

*Timeline of cervical cancer

"Cervical cancer vaccine". Ellensburg Daily Record. "Decreased Incidence of Cervical Cancer in Medicare‐Eligible California ... Timeline of lung cancer Timeline of brain cancer Timeline of kidney cancer Timeline of colorectal cancer Timeline of pancreatic ... cancer Timeline of liver cancer Timeline of bladder cancer "Cervical cancer: From Hippocrates through Rigoni-Stern to zur ... World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.12. ISBN 9283204298. World Cancer Report 2014. World ...

*Controversy

Saul, Stephanie; Andrew Pollack (2007-02-17). "Furor on Rush to Require Cervical Cancer Vaccine". The New York Times. ISSN 0362 ... Kahan, Dan M.; Donald Braman; Geoffrey L. Cohen; Paul Slovic; John Gastil (2008-07-15). "Who Fears the HPV Vaccine, Who Doesn't ... In other controversies - such as that around the HPV vaccine, the same evidence seemed to license inference to radically ...

*Immune-Related Response Criteria

"A clinical development paradigm for cancer vaccines and related biologics". J Immunother. 30 (1): 1-15. doi:10.1097/01.cji. ... The median overall survival for the ipilimumab+vaccine group was 10 months versus only 6.4 months for the vaccine. Marketed as ... Miller AB; Hoogstraten B; Staquet M; Winkler A. (January 1, 1981). "Reporting results of cancer treatment". Clin. Cancer Res. ... involves agents which harness the body's own immune system to fight cancer. Traditionally, patient responses to new cancer ...

*Phage display

... and the German Cancer Research Centre (Frank Breitling and Stefan Dübel). In 1991, The Scripps group reported the first display ... antibody Fab that bound tetanus toxin and the method was then extended to rapidly clone human anti-HIV-1 antibodies for vaccine ... The Scripps Research Institute with Lerner and Barbas and the German Cancer Research Center with Breitling and Dübel for ... for development into antibody drugs primarily as anti-cancer or anti-inflammatory therapeutics. One of the most successful was ...
TY - JOUR. T1 - The human vaccines project. T2 - A roadmap for cancer vaccine development. AU - Romero, Pedro. AU - Banchereau, Jacques. AU - Bhardwaj, Nina. AU - Cockett, Mark. AU - Disis, Mary L.. AU - Dranoff, Glenn. AU - Gilboa, Eli. AU - Hammond, Scott A.. AU - Hershberg, Robert. AU - Korman, Alan J.. AU - Kvistborg, Pia. AU - Melief, Cornelis. AU - Mellman, Ira. AU - Palucka, A. Karolina. AU - Redchenko, Irina. AU - Robins, Harlan. AU - Sallusto, Federica. AU - Schenkelberg, Theodore. AU - Schoenberger, Stephen. AU - Sosman, Jeffrey. AU - Türeci, Özlem. AU - Van Den Eynde, BenoÎt. AU - Koff, Wayne. AU - Couko, George. PY - 2016/4/13. Y1 - 2016/4/13. N2 - Cancer vaccine development has been vigorously pursued for 40 years. Immunity to tumor antigens can be elicited bymost vaccines tested, but their clinical efficacy remainsmodest.We argue that a concerted international effort is necessary to understand the human antitumor immune response and achieve clinically effective cancer ...
1.2 List of Figures. Figure 1: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Cervical Cancer, Patients (000), 2015-2022 17. Figure 2: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Liver Cancer, Patients (000), 2015-2022 18. Figure 3: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Melanoma, Patients (000), 2015-2022 19. Figure 4: Cancer Vaccines Market, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (000), 2015-2022 20. Figure 5: Cancer Vaccines Market, Global, Key Marketed Products and Approved Indications, 2016 31. Figure 6: Cancer Vaccines Market, Global, Annual Revenues for Gardasil ($bn), 2006-2022 33. Figure 7: Cancer Vaccines Market, Global, Annual Revenues for Provenge ($m), 2010-2022 34. Figure 8: Cancer Vaccines Market, Global, Annual Revenues for Cervarix ($m), 2007-2022 36. Figure 9: Cancer Vaccines Market, Global, Annual Revenues for Imlygic ($m), 2015-2022 37. Figure 10: Cancer Vaccines ...
WORCESTER, Mass. and TORONTO, Feb. 17, 2015 /CNW/ -- Generex Provides Update on Antigen Express Phase II AE37 Breast Cancer Vaccine Trial.
Vaccines that prevent disease have profoundly changed the lives of billions of people around the world," says Matthew M. Davis, M.D., MAPP, associate professor of pediatrics and internal medicine at the University of Michigan Medical School. "A national strategy for therapeutic cancer vaccines would help emphasize development and regulatory approval for vaccines targeting cancers that currently do not have other good therapeutic options ...
A prostate cancer vaccine test showed encouraging results last month. Inovio Pharmaceuticals, based out of Washington, D.C., announced in June that its DNA vaccine for prostate cancer demonstrated a significant immune response in monkeys. The company plans to start a Phase I clinical trial in 2012.. The development of a prostate cancer vaccine is still far away, and patients need to find help in the meantime. Here at Chicago Prostate Center, we encourage men over the age of 50 (40 years old if you have a family history or are African American) to get yearly prostate cancer screenings that include a PSA test and digital rectal exam (DRE). Early detection is extremely important to curing prostate cancer. Contact us today to find out more and make an appointment for a screening at CPC.. ...
TY - JOUR. T1 - Personalized dendritic cell-based tumor immunotherapy. AU - Janikashvili, Nona. AU - Laemonier, Nicolas. AU - Katsanis, Emmanuel. PY - 2010/1. Y1 - 2010/1. N2 - Advances in the understanding of the immunoregulatory functions of dendritic cells (DCs) in animal models and humans have led to their exploitation as anticancer vaccines. Although DC-based immunotherapy has proven clinically safe and efficient to induce tumor-specific immune responses, only a limited number of objective clinical responses have been reported in cancer patients. These relatively disappointing results have prompted the evaluation of multiple approaches to improve the efficacy of DC vaccines. The topic of this review focuses on personalized DC-based anticancer vaccines, which in theory have the potential to present to the host immune system the entire repertoire of antigens harbored by autologous tumor cells. We also discuss the implementation of these vaccines in cancer therapeutic strategies, their ...
Data & statistics on Cancer Vaccines: Number2of trials conducted by each lead sponsor Number of trials conducted by each lead sponsor. (a) The number of cancer vaccine trials conducted by each lead sponsor is plotted as a bar graph by the name of the sponsor. Only the sponsors who have conducted more than 10 cancer vaccine trials are depicted here. The height of the bar and the number on top of each bar represent the total number of trials ..., HIV/AIDS vaccines, malaria vaccines, tuberculosis vaccines, anti-cancer vaccines, anti-addiction vaccines anti-fertility vaccines, therapeutic vaccines., Konno, R., et al., Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer, 2010. 20(3): p. 385-392. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec, 2009. 84(15): p. 118-131. Quadrivalent vaccine against human papillomavirus to prevent...
Cancer is the leading cause of death worldwide. In developed as well as developing countries, breast cancer is the most common cancer found among women. Currently, treatment of breast cancer consists mainly of surgery, chemotherapy, hormone therapy, and radiotherapy. In recent years, because of increased understanding of the therapeutic potential of immunotherapy in cancer prevention, cancer vaccines have gained importance. Here, we review various immunotherapeutic breast cancer vaccines including peptide-based vaccines, whole tumor cell vaccines, gene-based vaccines, and dendritic cell vaccines. We also discuss novel nanotechnology-based approaches to improving breast cancer vaccine efficiency. ...
Positive Phase I Trial Results for Pevion Biotech Ltd.s and Bio Life Sciences Breast Cancer Vaccine - read this article along with other careers information, tips and advice on BioSpace
I am on a plane heading to speak to a multiple myeloma support group meeting today in Jackson, Mississippi. I just completed reading a series of articles in the last issue of Cure Magazine about the future of using cancer vaccines to fight cancer.. Magazine editor, Debu Tripathy, introduced the concept in his page 11 Message From the Editor. He began by stating "Cancer vaccines are no longer a long shot." Followig a long and technically detailed explanation of the challenges facing researchers in the field, Dr. Tripathy states: The main step to devise successful cancer vaccines has been to find cancer-specific targets-proteins or other substances that would single out cancer cells. However, since some cancercells originate from normal cells, it is nearly impossible to develop a tqarget that is not self. So the next barrier is to delicately maneuver the feedback mechanisms to allow a vigorous immune reaction to cancer cells.". His conclusion: "While the effectiveness of the immune response will ...
Despite recent advances in cancer immunotherapy, no prospectively validated intermediate biomarkers exist to predict response. These biomarkers are highly desirable given modern immunotherapys paradoxical pattern of clinical benefit; that is, improvement in overall survival without short-term change in progression. Immunotherapy clinical trials have evaluated biomarkers that may correlate with clinical outcomes. Many of them are performed on peripheral blood to evaluate the systemic response, such as tumor-targeted humoral and cellular immunity, and cytokine responses. Accumulating evidence suggests that immune infiltrates in tumors may suggest evidence for the therapys mechanism of action, and have greater potential for providing prognostic and predictive information. In addition, a non-immunologic biomarker, such as tumor growth kinetics, may explain this paradoxical pattern of clinical benefit, and predict survival in patients treated with an immunotherapy. Prospective assessment and validation of
Xinhua reported that Jerusalem-based Teva Pharmaceuticals and US-based Galena Biopharma are set to begin major clinical trials of a breast cancer treatment.
Personalized Ovarian Cancer Vaccine Shows Promise In Trial. Delegates in a conference in america now are listening to early outcomes of an effort of the new personalized ovarian cancer vaccine that. offers new expect the many patients who relapse after treatment.. Three-quarters of trial patients who received the brand new two-step immunotherapy made an appearance to reply to the therapy, including one patient who. achieved completed remission, say researchers in the Perelman Med school in the College of Pennsylvania.. Lead author from the study, Lana Kandalaft, an investigation assistant professor of Obstetrics and Gynecology and director of clinical development and. operations in Penn Medicines Ovarian Cancer Research Center, is presenting the findings on Wednesday in a Late Breaking Poster session from the. AACR 2013 Annual Meeting in Washington Electricity.. Kandalaft states inside a statement:. "This immunotherapeutic strategy has two steps - dendritic cell vaccination and adoptive T-cell ...
On our website we use cookies for desktops and mobile devices to improve the users experience on the website. A cookie is a small text file that is stored on your computer or on your mobile devices, when you visit the website By using our website, you accept how we use cookies, unless you disable them. Please note that if you disable or not accept cookies, some features, services or functionalities may not be available.OkRead more ...
On our website we use cookies for desktops and mobile devices to improve the users experience on the website. A cookie is a small text file that is stored on your computer or on your mobile devices, when you visit the website By using our website, you accept how we use cookies, unless you disable them. Please note that if you disable or not accept cookies, some features, services or functionalities may not be available.OkRead more ...
Immunotherapy has long been proposed as a novel method of specifically, safely and inexpensively treating cancer. Despite decades of research and hundreds of clinical trials, only one therapeutic cancer vaccine has been approved for human use. The vast majority of these clinical trials have been carried out in terminally ill patients with advanced cancer. These patients are severely immune compromised. The studies herein demonstrate that multiple immunosuppressive mechanisms develop within prostate tumors as they progress. These mechanisms include the accumulation of regulatory T cells in the prostate tumor, and increased expression of TGFβ and indoleamine 2,3 dioxygenase in the prostate tumor. Vaccination of mice with spontaneously arising prostate cancer against tumor-associated antigens is vastly superior to immunization at later stages of disease, when tumor microenvironments are more suppressive. A novel murine model of prostate cancer in which major mediators of immune suppression - ...
Immunotherapy has long been proposed as a novel method of specifically, safely and inexpensively treating cancer. Despite decades of research and hundreds of clinical trials, only one therapeutic cancer vaccine has been approved for human use. The vast majority of these clinical trials have been carried out in terminally ill patients with advanced cancer. These patients are severely immune compromised. The studies herein demonstrate that multiple immunosuppressive mechanisms develop within prostate tumors as they progress. These mechanisms include the accumulation of regulatory T cells in the prostate tumor, and increased expression of TGFβ and indoleamine 2,3 dioxygenase in the prostate tumor. Vaccination of mice with spontaneously arising prostate cancer against tumor-associated antigens is vastly superior to immunization at later stages of disease, when tumor microenvironments are more suppressive. A novel murine model of prostate cancer in which major mediators of immune suppression - ...
A therapeutic cancer vaccine from Oxford BioMedica that failed in a clinical study may still help a subset of patients, researchers said on Tuesday.
Current vaccine strategies for COVID-19 include mRNA vaccine, DNA vaccine, adenovirus vector-based vaccine and inactivated virus vaccine, with the goal of generating neutralizing antibody that reacts to Spike, the viral surface protein of COVID-19. The neutralizing antibody blocks entry of virus to host cells through ACE2 receptor. Accumulating evidences have suggested that developing permanent immunity remains challenging, exclusively by targeting heavily glycosylated Spike protein or rapidly mutating viral surface proteins such as influenza HA. Differing from these vaccine strategies, the engineered DCs are designed to empower T cells to fight virus. DC-educated T cells recognize viral antigenic peptides complexed with HLA molecules on the surface of virus-harboring host cells and launch subsequent attack to eliminate virus. Furthermore, a given viral protein in host cells is processed into multiple antigenic peptides that are bound to distinct HLA molecules, this provides many targets for ...
Therapeutic cancer vaccines have shown limited clinical efficacy so far. Nevertheless, in the meantime, our understanding of immune cell function and
The Center for Immunotherapy at Roswell Park Cancer Institute has launched a phase I clinical research study of a dendritic cell vaccine designed to both eradicate cancer cells and prevent disease relapse. The new cell vaccine will be manufactured in the Institutes new Therapeutic Cell Production Facility using a unique FDA-approved process - making RPCI the first research facility in the U.S. to use a custom-made barrier isolator for vaccine cell production, and the first in the world to use this system in an approved, government-regulated study ...
Principal Investigator:NAKAJIMA Jun, Project Period (FY):2012-04-01 - 2015-03-31, Research Category:Grant-in-Aid for Challenging Exploratory Research, Research Field:Thoracic surgery
At the ACGT anniversary gala in April, Robert Vonderheide, MD, DPhil, the Hanna Wise Professor in Cancer Research and newly appointed Director of the Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, briefed the audience on the progress of his research using immunotherapy for pancreatic cancer and other solid tumors. ACGT first supported Dr. Vonderheides innovative immunotherapy research for brain tumors, in 2003.. Now Dr. Vonderheide aims to develop a cancer vaccine, which may prove applicable to all human cancers. His team has identified an enzyme - Telomerase - present in all cancers. Known as a universal tumor antigen, telomerase has the potential to serve as a homing beacon for the immune systems killer T-cells. Early trials indicate a robust response, without toxicity, and also measurable survival benefits over time.. A vaccine for cancer? Yes, it is possible, but not quite what you know of a vaccine. A cancer vaccine does not introduce live pathogens ...
DC vaccines represent a promising therapy for cancer; however, their efficacy is frequently suboptimal. For example, a recent prostate cancer vaccine trial found that treatment resulted in a superior outcome, but the improvement in median survival was only 4.1 months (33). The very modest efficacy of DC vaccination was substantiated in our model by the vaccines inability to improve survival in WT mice. However, we found the efficacy of DC vaccination could be markedly improved in the absence of Nlrp3.. The effect of Nlrp3 in the tumor environment was unanticipated because the established signals for inflammasome priming and activation are not present. Our results and those of others suggest this concept is changing. Li and colleagues (35) have shown that the Nlrp3 inflammasome can be activated in a sterile setting by necrotic cancer cells. Priming is accomplished by an excess of extracellular matrix components and activation is completed by ATP released from dying cancer cells (36). These ...
www.MOLUNA.de Cancer Vaccines [4213771] - Cancer Vaccines: Methods and Protocols explores the manipulation and modification of immune cells, the manipulation and modification of tumor cells as well as the manipulation of immune/tumor interactions and various delivery mechanisms, with the overall end goal of evoking a tumor-specific response and overcoming the immuno-evasive mechanisms employed by the
Medimmune enters into strategic cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals Monday, 10 August 2015 Agreement includes clinical-stage INO-3112 HPV cancer vaccine and...
Drug giant Novartis is making a multimillion dollar bet that a patients immune system can be cancers worst enemy. It is teaming up with scientists at the University of Pennsylvania (UPenn) in Philadelphia to develop and manufacture cancer immunotherapies.. Last August, UPenn scientists announced the dramatic results of a tiny clinical trial of their immunotherapy approach, describing long-lasting remissions in leukaemia patients for whom standard therapies had stopped working. Trials are also underway for other leukaemias and for lymphoma, mesothelioma, myeloma and neuroblastoma, according to the university. In the US$20-million collaboration, announced today, Novartis, which is based in Basel, Switzerland, will get exclusive worldwide rights to these technologies.. The deal comes just a week after Dendreon, a biotechnology company based in Seattle, Washington, that developed the first cancer vaccine on the market, laid off 600 workers because of weak sales. Its drug, Provenge (sipuleucel-T), ...
EDMONTON, AB and DARMSTADT, GERMANY, April 2 /PRNewswire-FirstCall/ -- Biomira Inc. (NASDAQ:BIOM) (TSX:BRA) and Merck KGaA of Darmstadt, Germany, said today preliminary results from a randomized, open-label Phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non- small cell lung cancer (NSCLC) indicate that the median survival of those patients on the vaccine arm was 4.4 months longer than those on the control arm. Although not statistically significant, the overall median survival is 17.4 months for patients on the vaccine arm versus 13 months for the patients on the control arm. Importantly, the observed two-year survival for patients with locoregional Stage IIIb disease is 60 per cent for the vaccine arm (median survival not yet reached) versus 36.7 per cent for the control arm (median survival of 13.3 months). In the overall patient population the two-year survival is 43.2 per cent for the vaccine arm versus 28.9 per cent for the control arm. "Our overall ...
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline Plc (GSK) has stopped a high-profile clinical trial using a novel vaccine to fight lung cancer after deciding it will not be possible to find a sub-group of patients who might benefit. The decision comes less than two weeks after GSK said the MAGE-A3
This article provides a short historical overview of major lung cancer vaccination studies performed in the last decade to set the perspective on the development of current clinical trials of therapeutic cancer vaccines for patients with non–small cell lung cancer. 
ORLANDO -- More than half of men with metastatic, hormone-refractory prostate cancer had longer-than-estimated survival after treatment with an adenovirus/PSA vaccine, showed a phase I study.
CEO and Chairman of TapImmune, Dr. Glynn Wilson released a statement concerning the study noting, "This is our second T-cell vaccine candidate to be tested in a DoD-funded Phase 2 study to the Mayo Clinic, and it marks our expansion into a second breast cancer indication.". He explained that the study involving the new vaccine could potentially demonstrate the companys approach to treatment for both breast cancer and precancerous lesions. The fully funded study also opens the door for the company to test other products in its pipelines, including one for the treatment of ovarian cancer.". Keith Knutson, Ph.D., Director of the Discovery and Translational Labs Cancer Research Program at Mayo Clinics Florida campus will lead the study, which will enroll approximately 40-45 women with DCIS, all of whom will receive the vaccine six weeks in advance of standard surgical resection. TapImmunes vaccine has been shown to stimulate production of T-cells directed against breast cancer cells that ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Technology Networks is an internationally recognised publisher that provides access to the latest scientific news, products, research, videos and posters.
American scientists say they have developed a vaccine which has prevented breast cancer from developing in mice. The immunologist who led the research says the vaccine targets a protein found in most breast tumours. Vincent Tuohy, from the Cleveland Clinic Learner Research Institute, said: We believe that this vaccine will someday be used to prevent…
latest cancer vaccine deal looks better than the last, but it still isnt what Id call a stellar deal.. Youll recall that the biotech licensed its pancreas and prostate cancer vaccine to be used in combination with Aduro BioTechs CRS-207 for nothing up front. Zip. Zero. Nada.. BioSante was able to get something for licensing its melanoma vaccine, but the up front payment amounted to a measly $100,000. Thats not going to pay a whole lot of bills for its lead compound, LibiGel.. If the melanoma vaccine works, BioSante will be reap rewards on the back end. Its eligible for $39 million in milestone payments and undisclosed royalties on sales of the drug.. The licenser of the melanoma vaccine, the John P. Hussman Foundation, is an interesting choice for a partner. The nonprofit has dedicated $11 million to developing the drug, and it appears to be planning to ship it off to some larger drug developer once it has more clinical data. BioSante will get between 15% and 33% of the sublicense ...
The development of effective cancer vaccines remains an urgent, but as yet unmet, clinical need. cell responses associated with therapeutic benefit. Anti-tumor protection was dependent on cross-presenting Batf3+DC, pDC and CD8+T cells. CD103+DC from the skin/tumor dLN of the immunized mice appeared responsible for activation of Ag-specific na?ve CD8+T cells, but were dependent on pDC for optimal effectiveness. Similarly, human XBP1 improved the capacity of human blood- and skin-derived DC to activate human T cells. These data support an important intrinsic role for XBP1 in DC for effective cross-priming and orchestration of Batf3+DCCpDC interactions, thereby enabling Gap 27 effective vaccine induction of protective anti-tumor immunity. Keywords: XBP1, DC, Cancer Vaccines, Cross-priming, CD8+T cells Introduction Immunotherapies utilizing vaccines, antibodies, and T Gap 27 cells have the potential to (re)activate and optimize the bodys immune system to fight off cancer (1). Although vaccines are ...
The development of effective cancer vaccines remains an urgent, but as yet unmet, clinical need. cell responses associated with therapeutic benefit. Anti-tumor protection was dependent on cross-presenting Batf3+DC, pDC and CD8+T cells. CD103+DC from the skin/tumor dLN of the immunized mice appeared responsible for activation of Ag-specific na?ve CD8+T cells, but were dependent on pDC for optimal effectiveness. Similarly, human XBP1 improved the capacity of human blood- and skin-derived DC to activate human T cells. These data support an important intrinsic role for XBP1 in DC for effective cross-priming and orchestration of Batf3+DCCpDC interactions, thereby enabling Gap 27 effective vaccine induction of protective anti-tumor immunity. Keywords: XBP1, DC, Cancer Vaccines, Cross-priming, CD8+T cells Introduction Immunotherapies utilizing vaccines, antibodies, and T Gap 27 cells have the potential to (re)activate and optimize the bodys immune system to fight off cancer (1). Although vaccines are ...
1. Torensma R, Nelissen JM, van Kooyk Y, Raymakers RA, Pennings AH, de Witte T, Figdor CG. Regulation of LFA-1 Expression by CD34 Positive Cells and Inducible Growth Factor Production by Stroma Enable Formation of Bone Marrow Compartments; Subject Heading. Hematol, 2000. 5(4): 295-302.. 2. Schreurs MW, Eggert AA, Punt CJ, Figdor CG, Adema GJ. Dendritic cell-based vaccines: from mouse models to clinical cancer immunotherapy. Crit Rev Oncog, 2000. 11(1): 1-17.. 3. Vissers JLM, de Vries IJM, Oosterwijk E, Figdor CG, Adema GJ. 2000. Gp100 and G250: towards specific immunotherapy employing dendritic cells in melanoma and renal cell carcinoma. In Peptide-based cancer vaccines, ed. W Kast, pp. 200-21. Austin Tx), USA: Eureka.com. 4. Nelissen JM, Torensma R, Pluyter M, Adema GJ, Raymakers RA, van Kooyk Y, Figdor CG. Molecular analysis of the hematopoiesis supporting osteoblastic cell line U2-OS. Exp Hematol, 2000. 28(4): 422-32.. 5. Hartgers FC, Vissers JL, Looman MW, van Zoelen C, Huffine C, Figdor CG, ...
Promising research is underway to create a cancer vaccine for dogs with cancer. What is interesting about this approach is that the treatment is performed on an individual basis, where tumor cells are removed from the dog and then the cells are processed and combine with bacteria to then create a vaccine, tailored to that specific dog. The idea is that the vaccine will then cause the dogs immune system to attack the cancer cells, and in some case, has slowed the growth of the cancer and even resulted in remission. At this time, almost 30 dogs with advanced melanoma, bone and liver cancers have participated in trials, according to an article in The Dogington Post. Results of the trial are not yet available, as the researchers are filing patents first.. This technology is not new, however, and there is a DNA-based, melanoma vaccine that has been on the market since 2010 (but this existing vaccine does not incorporate cells from the dog). The article states that studies of dogs with Stage II and ...
Cancer immunotherapy can also be approached through the use of tumor cells as a platform to initiate a therapeutic immune response. Tumor cells by themselves are typically not immunogenic. However, as the science of determining how an effective APC initiates an immune response advance, these strategies are being used to alter tumor cells and render them as loci of immune stimulation. The most general method for cell-based immunotherapy is to use a single representative cancer cell as a universal vaccine for all patients with that same type of cancer. Some investigators consider this approach as suboptimal as it is allogeneic, where the MHC type of the vaccine and the patient do not match, and the immune system may be distracted from generating a tumor-antigen-specific to an allospecific response. Others argue that an allogeneic vaccine will be effective for just this reason, and that the alloimmune response will serve to amplify the cancer-antigen-specific response. This issue will be addressed ...
LONDON - Lung cancer is considered to be the most common cancer across the globe. In 2008 there were around 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers.. The needs of patients along with the high burden of lung cancer are key drivers for the development of new therapies. Though, there are improvements in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies building on the capabilities of existing approaches are strongly required.. At present, developments are being made in drug treatments for lung cancer, in chemotherapy, new drug combinations and targeted molecules. In particular, there are advancements in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.. New research report "Lung Cancer Vaccines: Pipeline, Strategies and Clinical" drawn up by Biopharm Reports ...
Synthetic antigen-encoding mRNA is increasingly exploited as a tool for delivery of genetic information of complete antigens into professional antigen presenting dendritic cells for HLA...
SCIB1 Trial Update: SCIB1 Clinical Trial: Recruitment for Phase I completed. Approval to start Phase II 17 April 2012 Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines,...
Back in 2010, Seattle-based Dendreon Corporation hit a medical milestone when its autologous vaccine for castration-resistant prostate cancer, Provenge (sipuleucel-T), became the first oncology immunotherapy approved by the U.S. Food and Drug Administration (FDA). Since then, the company has struggled with its business milestones. In recent months, Provenge sales have stalled, and in July Dendreon announced it would lay off 600 staff and close one of its facilities for producing the vaccine.. The companys misfortunes reflect heavy competition in prostate cancer treatment more than declining confidence in autologous vaccines for cancer, says Katherine Xu, PhD, an equity research analyst with William Blair & Co., in New York, NY. "If Provenge had been approved 10 years ago it would have had a much better launch," she says. "Weve got newer oral medications now with better survival data and better pricing.". Prepared by incubating a patients dendritic cells with an immune stimulator-granulocyte ...
A Ludwig Cancer Research study has shown that an entirely new type of personalized cancer vaccine induces novel, potent and clinically effective immune responses in patients receiving a combination of standard therapies for recurrent, stage III and IV ovarian cancer.
The development of nucleic acid based vaccines against cancer has gained considerable momentum through the advancement of modern sequencing technologies and on novel RNA-based synthetic drug formats, which can be readily adapted following identification of every patients tumor-specific mutations. Furthermore, affordable and individual on demand production of molecularly optimized vaccines should allow their application in large groups of patients. This has resulted in the therapeutic concept of an active personalized cancer vaccine, which has been brought into clinical testing. Successful trials have been performed by intranodal administration of sterile isotonic solutions of synthetic RNA vaccines ...
TARP is a protein that is found in about 95% of prostate cancers and is known to stimulate the immune system. The TARP prostate cancer vaccine is made from pieces of the TARP protein called peptides and includes peptides that have been modified to make them more effective at stimulating immunity. Although these TARP peptides have been shown to stimulate the immune systems of mice, information is needed to determine if they also stimulate the immune system in humans. Since it is unclear what is the best way to give peptide vaccines, the TARP peptides will be given with substances known to stimulate the immune system or in a vaccine made with the patient s own cells ...
For the last several years, veterinarians have noticed an increase in the incidence of sarcoma formation at commonly used feline vaccine sites. The
The keynote address was given by Stephen Hoffman of Celera. Confident that immunological interventions will ultimately have a greater impact on cancer therapy than monoclonal antibodies, Hoffman contends that protein targets as yet unidentified will demonstrate that immunological therapies can have an impact on the diseases of not just some, but most patients with cancer. He argued that the inadequate responses to current cancer vaccine targets observed to date relate to a lack of breadth of immune response against synthetic peptide or subunit targets, for example, HLA restriction of response is such that all individuals simply cannot respond to the same epitopes. Conversely, whole-cell vaccines, which might overcome the issue of breadth of response, present the opposite problem, that of failing to focus the immune response to the correct target. In the presence of too many proteins, unimportant proteins dilute or even suppress the immune response to the intended target. The proteomic approach ...
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not significantly impair the immune response. The paper was published on March 10 in the journal Cancer Immunology Research, an American Association for Cancer Research (AACR) publication.
5167 Over the past decade it has become clear that immunity to tumor antigens can be induced by immunization. However, in many cases the tumor antigen-specific immune response does not have an impact on tumor growth. One explanation for this is that vaccine adjuvants fail to generate a tissue destructive response, despite generating measurable immunity. A candidate adjuvant that could potentially be used to drive a tumor rejection immune response, due to its capability of generating self-antigen immunity, is uric acid (UA). UA has been recently identified as a natural endogenous warning molecule capable of alerting the immune system following its release from dying cells. The immune response generated augments the destruction and removal of the dying tissue and involves the activation of self-antigen specific immune effectors. In this study, we examined whether UA could function as a vaccine adjuvant in a mouse model of breast cancer. Vaccine (irradiated whole tumor cell vaccine) was given alone ...
Researchers advance a cancer vaccine to human trials as part of pioneering research aimed at treating incurable HPV cancers of the head, neck, throat and tongue.
An experimental cancer vaccine from GlaxoSmithKline has failed in a second test - this time against lung cancer - but the British company said it still hoped to identify a sub-group of patients in which it would work.
The genetic diversity between individual tumors makes it difficult to develop a universal cancer vaccine, but there are a lot of alternative treatments.
An international team of scientists has used DNA from healthy cells have been used to create a cancer vaccine to treat prostate…
[106 Pages Report] Check for Discount on Global Cancer Vaccines Market Professional Survey Report 2016 report by QYResearch Group. This report Mainly covers the following product types The segment...
Merck and Moderna Therapeutics have linked under a strategic collaboration and license agreement to develop and commercialise cancer vaccines based on novel messenger RNA. - News - PharmaTimes
INDIANAPOLIS and TÜBINGEN, Germany, Oct. 18, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVacs proprietary RNActive® technology.
Full-length tumor Ags are becoming increasingly available and are now being investigated in human cancer vaccine trials for their ability to induce T cell and humoral responses against tumors in patients regardless of a patients HLA haplotype. Extensive immunological monitoring carried out in our laboratories of patients immunized with recombinant NY-ESO-1 protein revealed that vaccination with NY-ESO-1 protein induced CD4+ T cell and Ab responses against NY-ESO-1 but the induction of CD8+ T cells was rather uncommon (12, 15). However, when NY-ESO-1 protein was formulated in delivery systems such as cholesterol-bearing hydrophobized pullulan or ISCOMATRIX, which facilitate cross-presentation of a formulated protein Ag (9, 11), or was administered with CpG 7909 in montanide (7), CD4+ and CD8+ T cell responses were observed, suggesting that immunization with protein Ags alone or combined with a weak adjuvant are inefficiently presented to the immune system. Even with these approaches, not all ...
Abstract The microenvironment of established tumours is often immunosuppressed, and this allows tumours to grow and disseminate without being eliminated by the patients immune sys..
Danish drugmaker Pharmexa says it plans to file for approval to start a second Phase III trial of its peptide anticancer vaccine GV1001 in pancreatic cancer within the next few weeks. - News - PharmaTimes
Purpose: NY-ESO-1 (ESO), a tumor-specific antigen of the cancer/testis group, is presently viewed as an important model antigen for the development of generic anticancer vaccines. The ESO119-143 region is immunodominant following immunization with a recombinant ESO vaccine. In this study, we generated DRB1*0101/ESO119-143 tetramers and used them to assess CD4 T-cell responses in vaccinated patients expressing DRB1*0101 (DR1).. Experimental Design: We generated tetramers of DRB1*0101 incorporating peptide ESO119-143 using a previously described strategy. We assessed ESO119-143-specific CD4 T cells in peptide-stimulated postvaccine cultures using the tetramers. We isolated DR1/ESO119-143 tetramer+ cells by cell sorting and characterized them functionally. We assessed vaccine-induced CD4+ DR1/ESO119-143 tetramer+ T cells ex vivo and characterized them phenotypically.. Results: Staining of cultures from vaccinated patients with DR1/ESO119-143 tetramers identified vaccine-induced CD4 T cells. ...
A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from The University of Texas.
The journal focuses on cancer metastasis and treatment. The coverage includes basic and clinical studies related to cancer cell, cell biology, oncology, radiation therapy and radiology, obstetrics and gynecology, pediatrics, surgery, hematology, neuro-oncology, etc.
In early clinical trials, vaccination with allogeneic cancer cells enhanced the overall survival in some patients with malignancies. Because the administered vaccine cells were cultured at pO2=20 kPa, it is unclear whether they provided an adequate antigen match to tumor cells in situ where pO2 is generally much lower. Thus, we postulate that hypoxically grown vaccine cells will provide a better antigen match to tumors in situ. We are testing this hypothesis by studying the effects of hypoxia on prostate cancer (CaP) cells. LnCaP and VCaP cells were cultured at pO2=2 kPa or 20 kPa and analyzed by 2-D gel electrophoresis. The difference in pO2 affected the proteome mostly quantitatively (i.e., by change in spot intensity). Using a threshold of fivefold change, we found that hypoxia decreased the levels of thirteen proteins and increased of four in VCaP cells. These results are in line with the reports showing that hypoxia affects expression only of a small fraction of total cellular protein and ...
New research in mice may be a first step toward a breast cancer vaccine for humans. The findings, published online Sunday and scheduled to run in the June 10 issue of the journal Nature Medicine, found that mice who were genetically engineered to be at high risk for breast cancer were effectively immunized against the disease after being. …. ...
New research in mice may be a first step toward a breast cancer vaccine for humans. The findings, published online Sunday and scheduled to run in the June 10 issue of the journal Nature Medicine, found that mice who were genetically engineered to be at high risk for breast cancer were effectively immunized against the disease after being. …. ...
A vaccine for one of the most lethal cancers, advanced melanoma, has improved response rate and progression-free survival for patients when combined with the immunotherapy drug Interleukin-2, according to a research by MD Anderson Cancer Center.
Health, ...CINCINNATICincinnati Cancer Center (CCC) and UC Cancer Institute resea...These findings published in the Feb. 27 online edition of the journal...Principal Investigator John Morris MD clinical co-leader of the Mole... Recently human Interleukin-15 (IL-15) has entered clinical trials fo...,Cancer,vaccine,could,use,immune,system,to,fight,tumors,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
One recurrent finding in recent large controlled immunotherapies studies for cancer has been improvedoverall survival (OS) without an improvement in median prog...
Martinez didnt get a rose, but she was swiftly removed from the Missing and Unidentified Persons Units list. Not so coincidentally, this timeline perfectly aligns with The Bachelors shooting schedule. The researchers said that in future doctors could inject a tumour before it was removed, so that the body could then get to work fighting unidentified cancer elsewhere in the body. When the researchers injected the two molecules into mouse tumors, they disappeared in less than 10 days. OX40 functions as a throttle for T cells, another type of immune cell crucial for battling tumors, and the anti-OX40 antibodies rev up these cells.. All have shown promise in different ways, but all have their limitations, such as nasty side effects, high costs and/or very involved preparation and treatment times. Those that werent had their tumors regress following a second treatment, with similar results observed in mice with breast, colon and melanoma tumors.. The Stanford team tested this in situ vaccination ...
Heres what we know: HPV infects the majority of reproductive-age people. Several strains of this virus have been linked to multiple aggressive cancers. There is a safe, effective vaccine against two major oncogenic strains - that is, the possibility to eradicate most cervical, anal, vaginal, and throat cancers. Heres what else we know: barely 1% of women have received the full immunization course (3 doses administered 2 and 6 months apart at around 12 years old) in developing regions, and about one-third of women have in developed countries. There are many factors that play into the socioeconomic discrepancy in vaccination rates - differences in public health infrastructure that lead to varying vaccine availability; Gardasil is one of the most expensive immunizations on the market; the 3-dose, multi-month course raises logistical issues. Furthermore, the data above only consider women, and absolute numbers for all people worldwide are probably even lower. HPV does not discriminate between ...
Immunotherapeutic vaccine called Rindopepimut showed positive results in prolonging survival in patients with newly diagnosed EGFRvIII-positive glioblastoma (GB), one of the most aggressive forms of brain cancer. 65 patients in 31 locations were choosen for the study known as ACT III. The overall historic survival rate for patients with GB selected to match those on the…
you probably think of a vaccine as something you get to prevent an infection like the flu. but it can be any compound thats put into your body to start an immune reaction.
Agenus is developing proprietary PhosphoSynVax™ vaccine platform, based on technology obtained from PhosImmune, for the treatment of cancers. The next
... The term cancer vaccine is often used to describe a process whereby a persons immune system is coaxed into recognizing and destroying malignant
A new cancer treatment which strengthens a patients immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK.
From the creation of flu vaccines and new cancer therapies to enhancing agriculture and developing biofuels, bioscience breakthroughs are transforming our world and our health at a rapid pace. However, many Americans are not aware of the critical role the US federal government plays in supporting biological research and discovery. We are looking for you to create an exciting, yet informative video to help educate Americans on how science is funded! The contest is open to individual entrants residing in the U.S. who are at least 13 years of age at the time of entry. The video should be between 1-4 minutes in ...
Patients injected with proteins taken from their own brain tumours live longer, according to preliminary results of a small clinical trial
This unit describes the use of retroviral vectors that can be successfully employed for gene transfer into both primary tumor cultures and established cell lines
Less than a decade after being hatched out of a Texas university, Houston-based Bellicum Pharmaceuticals is in the midst of clinical trials on two
if the trials continue to go well this will be an incredible breakthrough http www post-gazette com stories news health pitt-cancer-institute-announces-successful-early-human-trial-of-colon-cancer-vaccine-
Well, my proposal for the conference Cancer Vaccines for Girls? at Rutgers University was accepted -- now I just need to figure out how to get it done before May 16! ;-) Yesterdays New York Times had an interesting article on Vaccinating Boys for Girls Sake. I liked it because it made fun of the…
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral
Stomach Membrane Protien Tumor Lysate, 0.1 mg. Tissue total protein is prepared from whole tissue homogenates and presents a consistent pattern on SDS-PAGE analysis.
6. Alergostop vaccine. Our immune system is a perfect machine that protect us against infections, helps our body to repair damage tissues and even participates as facilitator in many metabolic reactions. Sometimes, stressors factors accumulate in the body and abnormal signaling occurs, thus a sensitive part of our immune system lose its pathway, and defected antibodies start to be produce, leading our body to allergies, inflammatory reactions, autoimmune process and even cancer. Alergostop is an autologous vaccine that reprograms our immune system to restore the balance and equilibrium of those antibodies that are failing and prepare our body for a better and faster response to other therapies ...
Removing tumors and detecting even the most slightly diseased tissue have become easier with the help of bright GFP and a GFP-expressing adenovirus. T
Tumors present an unique challenge to the immune response, and it is difficult to develop therapies to focus the power of the immune system towards eliminating tumors. This solution details what we know about the challenges in.
NEW CANAAN, CT- Cancer vaccines present an elusive goal, yet one that is increasingly within reach for biomedical researchers. Their hope is to offer physicians and cancer patients more and better therapy options than radiation and chemotherapy. The advancement of cancer vaccine research, from the bench to clinical trials, was the focus of the Sabin Vaccine Institutes 5th Annual Colloquium on Cancer Vaccines and Immunotherapy held this past March 5-8 at Walkers Cay in the Bahamas.. According to H.R. Shepherd, chairman of the Sabin Vaccine Institute, this years colloquium generated immense energy toward progress on cancer vaccine research and immunotherapy advances. Dr. Shepherd is a proponent of vaccines as therapeutic agents against many forms of cancer, having been treated successfully with BCG vaccine (traditionally a tuberculosis vaccine), which is a non-specific immuno-suppressant that has found a place in the treatment of bladder cancer. Colloquium participants were challenged by Dr. ...
In the article "Cancer Vaccines: Can They Improve Survival?" Dr. Dillman differentiates between the two key endpoints typically used to assess therapeutic cancer vaccines in clinical studies. As cancer vaccines are designed to stimulate an immune response to cancer cells and induce long-term memory recognition of a tumor, they may improve overall survival even if they do not appear to slow the progression of disease. Although measuring overall survival compared to progression-free survival would usually require longer clinical trials, overall survival may be the only relevant efficacy endpoint, the author concludes.. "This is a timely article considering the number of vaccine and antibody immunotherapy trials ongoing or planned," says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham. "The conclusion that overall survival is the best clinical endpoint for efficacy in therapeutic vaccine and antibody ...
Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that play a critical role in the induction of antitumor immunity. Therefore, various strategies have been developed to deliver tumor-associated antigens (TAAs) to DCs as cancer vaccines. The fusion of DCs and whole tumor cells to generate DC-tumor fusion cells (DC-tumor FCs) is an alternative strategy to treat cancer patients. The cell fusion method allows DCs to be exposed to the broad array of TAAs originally expressed by whole tumor cells. DCs then process TAAs endogenously and present them through major histocompatibility complex (MHC) class I and II pathways in the context of costimulatory molecules, resulting in simultaneous activation of both CD4+ and CD8+ T cells. DC-tumor FCs require optimized enhanced immunogenicity of both DCs and whole tumor cells. In this context, an effective fusion strategy also needs to produce immunogenic DC-tumor FCs. We discuss the potential ability of DC-tumor FCs and the recent progress in improving
Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canadas Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million.The deal is subject to higher and better offers and extended the bid deadline to Feb. 10 for interested parties to participate in an auction, Dendreon said on Thursday.A stalking-horse bidder often helps draw others to an auction by setting a floor price, but they also require the bankrupt company to commit to paying break-up and other fees if the stalking horse is outbid.Seattle-based Dendreon filed for bankruptcy protection in November, after sales of Provenge fell short of expectations and left the company deep in debt ...
Toll-like receptor (TLR) ligands are increasingly being used as adjuvants in cancer vaccine trials to harness innate immunity and prime effective antitumor immune responses. Despite some success, enhancing tumor antigen presentation, promoting a protective antitumor response, and overcoming the immunosuppressive tumor microenvironment pose considerable challenges that necessitate further improvements in vaccine design. Here, we show that expression of the TLR ligand flagellin within tumor cells constitutes an effective antitumor vaccination strategy that relies on simultaneous engagement of TLR5 and the Nod-like receptors (NLRs) NLRC4/NAIP5 (neuronal apoptosis inhibitory protein 5) by flagellin along with associative recognition of tumor antigen for optimal antigen presentation to T cells. Although TLR5 signaling was critical for mediating rapid macrophage-dependent clearance of flagellin-expressing tumor cells in vivo, TLR5 and NLRC4/NAIP5 were equally important for priming antitumor CD4+ and ...
... PARIS and TORONTO Sept. 17 /- Sanofi pasteur thev... The MEL11 study uses an entirely new treatment approach toadvanced-s...The vaccine candidate is uniquely designed to stimulate the bodys own...,Multi-Pronged,Therapeutic,Cancer,Vaccine,Regimen,to,be,Studied,in,Melanoma,Patients,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health
Dendritic cells (DCs) are professional antigen-presenting cells of the immune system with the ability to induce and control T and B cells responses. Monocytes have been used as precursors to generate DC vaccines ex vivo. Monocyte-derived DCs have been used as vaccines in clinical trials to treat cancer and infectious disease by eliciting potent T cell responses. Infection with Human Immunodeficiency Virus (HIV) almost invariably leads to a chronic disease. Eventually the destruction of the immune system culminates into Acquired Immune Deficiency Syndrome (AIDS). Since the advent of Highly Active Antiretroviral Therapy (HAART), HIV patients have been able to control viral levels. However, with prolonged use of treatment, these patients experience serious adverse effects such as liver and mitochondrial toxicity that can potentially become fatal. Long-Term Non-Progressors (LTNP) are a unique subpopulation of HIV patients that are able to control their viral load without HAART. Studies revealed ...
TY - JOUR. T1 - Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. AU - Liau, Linda M.. AU - Prins, Robert M.. AU - Kiertscher, Sylvia M.. AU - Odesa, Sylvia K.. AU - Kremen, Thomas J.. AU - Giovannone, Adrian J.. AU - Lin, Jia W.. AU - Chute, Dennis J.. AU - Mischet, Paul S.. AU - Cloughesy, Timothy F.. AU - Roth, Michael D.. PY - 2005/8/1. Y1 - 2005/8/1. N2 - Purpose: We previously reported that autologous dendritic cells pulsed with acid-eluted tumor peptides can stimulate T cell - mediated antitumor immune responses against brain tumors in animal models. As a next step in vaccine development, a phase I clinical trial was established to evaluate this strategy for its feasibility, safety, and induction of systemic and intracranial T-cell responses in patients with glioblastoma multiforme. Experimental Design: Twelve patients were enrolled into a multicohort dose-escalation ...
... , How Does a Dendritic Cell Vaccine Work?, Ralph Steinman, Nobel prize winner, speaks about dendritic cells and immune-based vaccines, AHI Functional Oncology Lecture Series - Dendritic Cell Cancer Vaccine
Recently, the US FDA approved sipuleucel-T, which is composed of autologous DCs stimulated with a recombinant fusion protein of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), as the first immunotherapeutic agent for metastatic castration resistant prostate cancer (mCRPC). However, sipuleucel-T demonstrated only modest efficacy in mCPRC patients. Researchers are now investigating the potential of p53 protein as a tumor-associated antigen (TAA) loaded in DC-based cancer vaccine. Approximately half of all tumors overexpress p53, and up to 20% of prostate cancer cells overexpresses p53. In this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro. We successfully generated the p53-DC vaccine by culturing autologous DCs infected with rAd-p53. This p53-DC vaccine can differentiate CTLs specifically cytotoxic to p53-overexpressing prostate cancer
BACKGROUNDː The most cause of cancer-related death in women population is breast cancer (BC). Hence, efforts to develop an effective treatment against BC are needed. Since the large proportion of BC is due to over-expression of tumor-associated antigens (TAAs), multi-epitope cancer vaccines are considered as a promising therapeutic approach. The aim of the current study is the production of the novel multi-epitope peptide vaccine against BC in a prokaryotic host. Our novel multi-epitope BC vaccine consists of four sections: 1) cytotoxic T lymphocytes epitopes from human epidermal growth factor receptor, heparanase, mucin 1 protein; 2) helper T lymphocytes epitopes from survivin; 3) a segment of Por B protein a immunostimulatory adjuvant, which was selected from Neisseria meningitides by bioinformatics analysis; 4) a segment of murine ULBP-like transcript 1, which binds to a natural killer group 2 member D receptor in tumor microenvironment with high affinity and stimulates innate immune ...
The human papillomavirus (HPV) vaccine works for women aged 24 to 45 in Woodhaven who arent already infected by HPV, the virus that has been linked to cervical cancer and other cervical diseases. Thats the finding from Dr. Nubia Munoz, of the National Institute of Cancer in Bogota, Columbia, who noted that womens rising age at first marriage and increasing divorce rates have led to more widespread premarital intercourse and pairing with new sexual partners around middle age.
Mesothelioma patients who are not candidates for surgery may soon have another treatment option. The FDA has granted orphan drug approval to a new cancer vaccine called CRS-207. CRS-207 is manufactured by Aduro Biotech, Inc. and is made from an attenuated (less potent) version of the bacteria Listeria monocytogenes. CRS-207 triggers a powerful immune response against cells that produce mesothelin, a tumor-associated antigen produced by several types of cancer, including mesothelioma. Because it works in conjunction with the bodys natural immune responses, CRS-207 is classified as a type of immunotherapy. Aduro Biotech is currently enrolling mesothelioma patients in a Phase 1b clinical trial of CRS-207. They are looking for 40 mesothelioma patients who have inoperable cancer and have not yet … Continue reading Mesothelioma Vaccine Receives Orphan Drug Approval » ...
The ligands and inhibitory receptors that regulate T cell effector functions are mostly overexpressed on tumor-infiltrating immune cells or on tumor cells in the tumor microenvironment. Therefore, targeting these ligands and receptors is relatively specific to tumors compared to normal tissues. It is within these tumor microenvironments that immune effector cells acquire inhibitory receptors, resulting in T cell dysfunction. Soluble molecules include cytokines with immunosuppressive activity, such as IL-10, transforming growth factor (TGF)-β, and IL-27, which regulate immune responses to tumor cells and induce T cell dysfunction within the tumor microenvironment [99-102]. The IL-10 pathway has been intensively studied for its role in T cell dysfunction in chronic viral infections and cancer [99, 100]. IL‑10 promotes T cell exhaustion, and IL‑10 blockade reverses T cell dysfunction during chronic viral infections [99]. Co-blockade of both IL-10 and the PD1 reverses CD8+ T cell exhaustion and ...
This work aims to develop a new, facile, and rapidly applied melanoma treatment for post-surgery melanoma patients to prolong or preserve their lives. Micro-scale needle arrays will be used as the drug delivery platform, for a highly controlled transcutaneous delivery of cancer vaccines. Layer-by-layer polyelectrolyte assembly will be used to generate the drug releasing thin film coatings on microneedles.. A microneedle platform for effective gene delivery is designed, with an effective release polymer that assists LbL film construction and implantation upon application in the skin. The DNA and/or RNA therapeutic cargos will be engineered with functional proteins and polymer scaffolds to enhance expression. This application seeks to achieve a staged release of melanoma cancer vaccines in order to activate a robust immune response; through direct insertion of microneedles into the dermis at or near the melanoma tumor site, a combination of tumor antigen present at the site and encapsulated ...

Cancer vaccine - WikipediaCancer vaccine - Wikipedia

A cancer vaccine is a vaccine that either treats existing cancer or prevents development of a cancer. Vaccines that treat ... "Oral vaccine could fight source of stomach cancers". Vaccine News Reports.. *^ Giarelli E (2007). "Cancer vaccines: a new ... This article is about therapeutic cancer vaccines. For preventive cancer vaccine, see cancer immunoprevention. ... Traditional vaccines[edit]. Some types of cancer, such as cervical cancer and some liver cancers, are caused by viruses ( ...
more infohttps://en.wikipedia.org/wiki/Cancer_vaccine

Cancer vaccines | The BMJCancer vaccines | The BMJ

Cancer vaccines are designed to promote tumor specific immune responses, particularly cytotoxic CD8 positive T cells that are ... thereby having cancer vaccine effects. The monitoring of patients immune responses at baseline and after standard of care ... Cancer vaccines. BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h988 (Published 22 April 2015) Cite this as: BMJ 2015;350:h988 ... The earliest vaccines, which were developed in 1994-95, tested non-mutated, shared tumor associated antigens that had been ...
more infohttp://www.bmj.com/content/350/bmj.h988

Handbook of Cancer Vaccines | SpringerLinkHandbook of Cancer Vaccines | SpringerLink

The quest to harness the immune system for the treatment of cancer has been of great interest for more than 100 years, but new ... In Handbook of Cancer Vaccines, leading scientific investigators and clinicians distill the vast body of literature on cancer ... DNA cancer cell clinical trial cytokine cytokines immunotherapy melanoma ovarian cancer prostate cancer proteins tumor vaccine ... Antibody-Inducing Cancer Vaccines Against Cell-Surface Carbohydrate Antigens Govind Ragupathi, John Gathuru, Philip O. ...
more infohttps://link.springer.com/book/10.1007/978-1-59259-680-5

JCI -
Therapeutic cancer vaccinesJCI - Therapeutic cancer vaccines

Cancer Immunotherapy * Therapeutic cancer vaccines Cornelis J.M. Melief et al. * From mice to humans: developments in cancer ... Therapeutic cancer vaccines cannot be expected to act as a monotherapy. Cancer vaccines have been vilified because they do not ... Cancer vaccines must utilize an effective route of administration. The preferred routes of cancer vaccine administration must ... Clinical cancer vaccines against nonviral antigens. *Clinical experience with therapeutic vaccines against human cancer viruses ...
more infohttps://www.jci.org/articles/view/80009

Cancer Vaccines : Pharmaceuticals : UKCancer Vaccines : Pharmaceuticals : UK

Cancer Vaccines. 27th September to 28th September 2017, London, United Kingdom. Growing year on year, Cancer Vaccines 2017 ... 14:10 Immune modulation as an essential tool for cancer vaccines. • Cancer vaccines require an optimal adjuvant. • The work ... Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and ... Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and ...
more infohttp://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=EBTech

Cancer Vaccines : Pharmaceuticals : UKCancer Vaccines : Pharmaceuticals : UK

Cancer Vaccines. 27th September to 28th September 2017, London, United Kingdom. Growing year on year, Cancer Vaccines 2017 ... 14:10 Immune modulation as an essential tool for cancer vaccines. • Cancer vaccines require an optimal adjuvant. • The work ... Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and ... Vaccine, Immunology, European Journal of Cancer, Cancer Therapy, Amino-Acids, vaccine supplement and Medicinal Chemistry and ...
more infohttp://www.smi-online.co.uk/pharmaceuticals/uk/conference/cancer-vaccines

Directory | Cancer Vaccine InstituteDirectory | Cancer Vaccine Institute

Members of the Cancer Vaccine Institute are faculty of UW Medicine, Seattle Cancer Care Alliance and Fred Hutchinson Cancer ... Cancer Vaccine InstituteDiscover - Translate - Cure850 Republican St., Seattle, WA 98109 ... The Tumor Vaccine Group is a group of multidisciplinary investigators who work to support a comprehensive research effort for ... evaluating the role of the immune system in modulating cancer and develop novel therapies that will impact the lives of people ...
more infohttp://depts.washington.edu/tumorvac/directory?field_staff_category_tid=1

Cancer vaccines - Canadian Cancer SocietyCancer vaccines - Canadian Cancer Society

Cancer vaccines are used to: prevent a cancer from developing (prophylactic, or preventive, vaccine) treat a ca ... Most vaccines are used to prevent infectious diseases caused by viruses, such as the flu, measles or polio. ... A vaccine stimulates the immune system to produce antibodies to fight a disease. ... Vaccines to treat cancer. Cancer treatment vaccines can be made up of cancer cells, parts of cancer cells or antigens. These ...
more infohttp://www.cancer.ca/en/cancer-information/diagnosis-and-treatment/chemotherapy-and-other-drug-therapies/cancer-vaccines/?region=mb

Cancer Vaccines FundingCancer Vaccines Funding

eg.(cancer,cancers)(cervical,cervix)!("Squamous cell carcinoma",SCC). will return records where either the words cancer or ... Cancer Vaccines Funding This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to ... Request for Proposals (RFP) N01CN87006-18 "PREVENT Cancer Preclinical Drug Development Program: cGMP Production of Vaccines and ... Pancreatic Cancer Action Network-American Association for Cancer Research Research Acceleration Network Grants. Letter of ...
more infohttps://medworm.com/cancer-vaccines/funding/

Clinical Trials | Cancer Vaccine InstituteClinical Trials | Cancer Vaccine Institute

Members of the Cancer Vaccine Institute are faculty of UW Medicine, Seattle Cancer Care Alliance and Fred Hutchinson Cancer ... Breast CancerWe may have studies for Stage I, II, III, and IV breast cancer patients. Study eligibility may allow for patients ... Ovarian CancerWe could have studies open for ovarian cancer patients at any stage. The eligibility may allow for patients who ... Cancer Vaccine InstituteDiscover - Translate - Cure850 Republican St., Seattle, WA 98109 ...
more infohttp://depts.washington.edu/tumorvac/clinical-trials

Strategies for Cancer Vaccine DevelopmentStrategies for Cancer Vaccine Development

B. Acres and J.-Y. Bonnefoy, "Clinical development of MVA-based therapeutic cancer vaccines," Expert Review of Vaccines, vol. 7 ... "Cancer vaccines: preclinical studies and novel strategies," Advances in Cancer Research, vol. 95, pp. 115-145, 2006. View at ... Strategies for Cancer Vaccine Development. Matteo Vergati, Chiara Intrivici, Ngar-Yee Huen, Jeffrey Schlom, and Kwong Y. Tsang ... W. J. Lesterhuis, I. J. M. de Vries, G. J. Adema, and C. J. A. Punt, "Dendritic cell-based vaccines in cancer immunotherapy: an ...
more infohttps://www.hindawi.com/journals/bmri/2010/596432/ref/

Girls Should Get Cancer Vaccine - RedorbitGirls Should Get Cancer Vaccine - Redorbit

PENILE CANCER. Clinical trials have shown that a three-dose course of the vaccine can prevent close to 100 percent of the ... s Gardisil vaccine aimed at preventing a sexually transmitted virus that can cause cancer, a panel of U.S. experts said on ... "I think this is going to be a great cancer prevention tool but it is not going to be effective for about 10 years," said Dr. ... It will be up to insurers to decide whether to pay for the $125-a-dose vaccine, school districts and universities to require or ...
more infohttp://www.redorbit.com/news/health/554732/girls_should_get_cancer_vaccine/

Changing the timing of cancer vaccinesChanging the timing of cancer vaccines

They are key to cancer vaccines that seek to alert the immune system to presence of cancer by making it aware of tumor antigens ... A molecule specially modified by researchers at Baylor College of Medicine can reset the biological clock for cancer vaccines, ... The makers of cancer vaccines would like to activate the dendritic cells, expose them to the tumor antigens and then reinject ... This prolongs the time during which the cancer vaccines can undertake their task, he said. Dendritic cells are important ...
more infohttp://www.innovations-report.com/html/reports/medicine-health/report-39266.html

Cancer Vaccine Exists, Goes Unused - The AtlanticCancer Vaccine Exists, Goes Unused - The Atlantic

The HPV vaccine could prevent thousands of people every year from getting cancer. But a new CDC report says most children still ... Cancer Vaccine Exists, Goes Unused. The HPV vaccine could prevent thousands of people every year from getting cancer. But a new ... and the meningitis vaccines are all now part of the Vaccines for Children program, which provides free vaccines to uninsured ... Every 20 minutes a person in the U.S. is diagnosed with with a human-papilloma virus-associated cancer. Most of those cancers ...
more infohttps://www.theatlantic.com/health/archive/2014/07/theres-a-vaccine-that-can-prevent-cancer-most-people-arent-getting-it/375027/

Can cancer vaccines prolong survival? | EurekAlert! Science NewsCan cancer vaccines prolong survival? | EurekAlert! Science News

... should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials, in a provocative new article ... Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have ... As cancer vaccines are designed to stimulate an immune response to cancer cells and induce long-term memory recognition of a ... Therapeutic anti-cancer vaccines developed to treat metastatic disease such as advanced prostate cancer or melanoma rarely have ...
more infohttps://www.eurekalert.org/pub_releases/2015-04/mali-ccv040615.php

Handbook of Cancer Vaccines | Michael A. Morse | SpringerHandbook of Cancer Vaccines | Michael A. Morse | Springer

... and their current uses in treating cancer. The authors examine the basic issues that effect all vaccines (such as immune ... An authoritative survey of the scientific background for therapeutic cancer vaccines, the challenges to their development, ... In Handbook of Cancer Vaccines, leading scientific investigators and clinicians distill the vast body of literature on cancer ... Handbook of Cancer Vaccines. Editors: Morse, Michael A., Clay, Timothy M., Lyerly, H. Kim (Eds.) ...
more infohttps://www.springer.com/us/book/9781588292094?wt_mc=ThirdParty.RD.3.EPR653.About_eBook

Personalized ovarian cancer vaccines set for human trialsPersonalized ovarian cancer vaccines set for human trials

The method is being used to create personalized vaccines for ovarian cancer. ... Researchers have found a way to identify protein mutations in cancer cells. ... Testing the vaccine against ovarian cancer in humans. The team plans to test the vaccine in patients with ovarian cancer this ... Vaccine made up of cancer cell epitopes induced cancer resistance in mice. Co-principal investigator and bioinformatics ...
more infohttps://www.medicalnewstoday.com/articles/284055.php?sr

New approach to cancer vaccinesNew approach to cancer vaccines

An international team of scientists has used DNA from healthy cells have been used to create a cancer vaccine to treat prostate ... Cancer vaccines are not new and unlike traditional vaccines which protect against infection, they work by making the immune ... An international team of scientists has used DNA from healthy cells have been used to create a cancer vaccine to treat prostate ... The researchers think the principle could be applied to other cancers and have begun studies on melanoma. ...
more infohttp://theconversation.com/new-approach-to-cancer-vaccines-1926

New Treatment Boosts Cancer VaccineNew Treatment Boosts Cancer Vaccine

... included nine patients with advanced cancers who had previously received cancer vaccines. Three of the patients with metastatic ... Their research showed that blocking CTLA-4 maintains the response of T cells triggered by the vaccines to attack the cancer. ... an antibody that blocks CTLA-4 and showed that it enhances the cancer-fighting activity of certain anti-cancer vaccines. ... melanoma and two with ovarian cancer had received a vaccine produced by extracting their own cancer cells, engineering the ...
more infohttp://www.innovations-report.com/html/reports/medicine-health/report-17488.html

New Cancer Vaccine Target Discovered | GENNew Cancer Vaccine Target Discovered | GEN

New Cancer Vaccine Target Discovered * A new type of white blood cell has been identified that activates a killing immune ... will help scientists to design better targeted vaccine strategies to treat cancer and infections. ... Breast Cancer Recycles Toxic Waste to Restock Nitrogen for Growth * FDA Approves Gilead CAR-T Therapy Yescarta, Plans ... Cancer Immunotherapy? Theres a Synthetic Gene Circuit for That * Ring in the New: Rady Childrens Hospital Introduces NovaSeq ...
more infohttps://genengnews.com/gen-news-highlights/new-cancer-vaccine-target-discovered/81247109/

Universal Cancer Vaccine: Why Its UnlikelyUniversal Cancer Vaccine: Why It's Unlikely

The genetic diversity between individual tumors makes it difficult to develop a universal cancer vaccine, but there are a lot ... Vaccines to treat certain types of cancer A broad approach aside, vaccines can be used to treat specific types of cancer. ... Vaccines to prevent specific cancers. Diamond said there are obstacles to preventive vaccines for specific cancers. ... I dont think there will be a single vaccine or pill to treat all cancers. But thats not a requirement for cancer treatment. ...
more infohttps://www.healthline.com/health-news/cancer-vaccine-unlikely-but-do-we-need-one

Allogeneic Antigen Composition for Preparing Universal Cancer VaccinesAllogeneic Antigen Composition for Preparing Universal Cancer Vaccines

... cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and ... Allogeneic Antigen Composition for Preparing Universal Cancer Vaccines. Petr G. Lokhov1,2 and Elena E. Balashova1,2 ... in the presence of respective adjuvants may be clinically tested as a therapeutic or prophylactic universal cancer vaccine ... We demonstrated that allogeneic SANTAVAC (Set of All Natural Target Antigens for Vaccination Against Cancer), which presents a ...
more infohttps://www.hindawi.com/journals/jir/2016/5031529/abs/

Have scientists found an anti-cancer vaccine?Have scientists found an anti-cancer vaccine?

... which they tested in 75 mice with various types of cancer. Heres what they found. ... Researchers used stem cells to create an anti-cancer vaccine, ... Cancer / Oncology Breast Cancer Lung Cancer Melanoma / Skin ... And, the same thing happened in lung and skin cancer models.. "What surprised us most was the effectiveness of the iPSC vaccine ... Over time, this led scientists to believe that embryonic stem cells could be used as a sort of vaccine against cancer tumors. ...
more infohttps://www.medicalnewstoday.com/articles/320941.php?iacp

Bionformatics Researchers Develop Personalized Cancer VaccinesBionformatics Researchers Develop Personalized Cancer Vaccines

The goal is to develop a safe and effective cancer vaccine specifically designed for each patient. This research has the ... Bionformatics Researchers Develop Personalized Cancer Vaccines. Computer Science & Engineering (CSE) Associate Professor Ion ... can then be used as personalized vaccines to elicit a protective T cell response that destroys the cancer. In their study, ... Pramod Srivastava, director of the Carole and Ray Neag Comprehensive Cancer Center at UConn Health, on a study leading to the ...
more infohttps://www.cse.uconn.edu/news/front-page/bionformatics-researchers-develop-personalized-cancer-vaccines/

Cancer Vaccines Market Growth Analysis & Key BusinessCancer Vaccines Market Growth Analysis & Key Business

... Strategies by Leading Industry Players: Astrazeneca Plc. (Medimmune, LLC ... Moreover, cancer vaccines are expected to reduce the prevalence and incidence rate of cancer.. The global cancer vaccines ... cervical cancer, prostate cancer, lung cancer, breast cancer, and others. These vaccines are designed specifically to recognize ... administration of prophylactic cancer vaccines, high investments & government funding in the development of cancer vaccines, ...
more infohttps://www.openpr.com/news/1267821/cancer-vaccines-market-growth-analysis-key-business-strategies-by-leading-industry-players-astrazeneca-plc-medimmune-llc-glaxosmithkline-plc-merck-co-inc-sanofi-pasteur-aduro-biotech-inc-sanpower-group-astellas-pharma-inc-csl-limite.html
  • Most cancer treatment vaccines are still being studied in clinical trials. (cancer.ca)
  • Clinical trials have shown that a three-dose course of the vaccine can prevent close to 100 percent of the lesions that can become cervical cancer, and genital warts. (redorbit.com)
  • Robert O. Dillman, MD, NeoStem, Inc., asserts that "overall survival" rather than "progression-free survival" should be the gold standard for evaluating the efficacy of cancer vaccines in clinical trials, in a provocative new article published in Cancer Biotherapy and Radiopharmaceuticals , a peer-reviewed journal from Mary Ann Liebert, Inc., publishers . (eurekalert.org)
  • Topics of particular interest include the clinical results for cancer vaccines now beginning to be used in the treatment of many common cancers, the monitoring of biologic responses to these vaccines, and the statistical and regulatory issues affecting the design and conduct of their clinical trials. (springer.com)
  • The third section looks at the results of vaccine-based clinical trials for various malignancies. (springer.com)
  • Other companies, including Bristol-Myers Squibb Co, Roche Holding AG and Merck & Co Inc, have had some recent notable successes in clinical trials of innovative drugs to boost the immune system, but GSK's vaccine-based approach is different and has met with less success. (yahoo.com)
  • Cancer vaccines seek to target a tumor-specific antigen and distinct from self-proteins. (wikipedia.org)
  • The authors examine the basic issues that affect all vaccines (such as immune adjuvants and prime-boost strategies), describe cutting-edge methods for antigen discovery, and review the preclinical development phases for each major vaccine strategy. (springer.com)
  • Effective cancer vaccines deliver concentrated antigen to both HLA class I and II molecules of DCs, promoting both CD4 and CD8 T cell responses. (jci.org)
  • In many phase I/II studies, these vaccines have shown clinical benefit, in particular extended overall or disease-free survival, while objective durable regressions of the type associated with targeted or immunomodulatory mAb therapy ( 2 - 6 ) or chimeric antigen receptor (CAR) ( 7 - 10 ) or adoptive T cell ( 11 , 12 ) therapy were rarely seen. (jci.org)
  • Whole tumour vaccines use the whole cancer cell, not just an antigen, to make the vaccine. (cancer.ca)
  • As the researchers explain, the main advantage of using whole iPSCs is that the vaccine no longer has to identify the perfect antigen to target in a specific kind of cancer. (medicalnewstoday.com)
  • The decision comes less than two weeks after GSK said the MAGE-A3 therapeutic vaccine did not help patients with non-small cell lung cancer in the Phase III study overall, but it was still looking for improvements among patients with a particular genetic profile. (yahoo.com)
  • These are the cells we need to be targeting for anticancer vaccines," says Muzlifah Haniffa, M.D., Ph.D., a Wellcome Trust Intermediate Fellow and senior clinical lecturer at Newcastle University. (genengnews.com)
  • On April 14, 2009, Dendreon Corporation announced that their Phase III clinical trial of sipuleucel-T , a cancer vaccine designed to treat prostate cancer, had demonstrated an increase in survival. (wikipedia.org)
  • It received U.S. Food and Drug Administration (FDA) approval for use in the treatment of advanced prostate cancer patients on April 29, 2010. (wikipedia.org)
  • Sipuleucel-T, Provenge , was approved by the FDA in April 2010 for metastatic hormone-refractory prostate cancer . (wikipedia.org)
  • The first prostate cancer vaccine could be a step away after ministers gave their approval for a human trial of a new genetically modified therapy. (telegraph.co.uk)
  • The treatment, developed by Bavarian-Nordic Immunotherapeutics, is aimed at men with advanced prostate cancer which cannot be cured by castration and for whom treatment options are very limited. (telegraph.co.uk)
  • The treatment, which uses viruses carrying human DNA to direct the body's natural defences against cancer cells, is the first prostate cancer vaccine ever to reach late stage "phase three" trials in Europe. (telegraph.co.uk)
  • No vaccines have yet been approved in Britain to treat any type of cancer, and scientists believe it could not only double the survival rate of prostate cancer sufferers but give way to a new range of similar treatments for other tumour types. (telegraph.co.uk)
  • Prostate cancer is the most common cancer among men and mainly occurs in those over 50, with 36,000 new cases being diagnosed each year. (telegraph.co.uk)
  • He said: "It is now being tested in patients who already have prostate cancer, as a treatment rather than a prevention, but one of the attractions with a therapy like this is we can move it to earlier stages, and maybe eventually use it preventively. (telegraph.co.uk)
  • Dr Kate Holmes, Head of Research at The Prostate Cancer Charity said: "This vaccine will not prevent prostate cancer, however results to date show it may be an exciting breakthrough for the treatment of men in the final stages of the disease. (telegraph.co.uk)
  • Men with advanced prostate cancer currently have very few treatment options available to them and if proven successful in the third trial phase this new vaccine would offer these men an urgently needed additional life extending treatment once other available options have stopped working. (telegraph.co.uk)
  • It is marketed by Antigenics Inc. Sipuleucel-T, Provenge, was approved by the FDA in April 2010 for metastatic hormone-refractory prostate cancer. (wikipedia.org)
  • Standard of care treatments, such as surgery and ablation, chemotherapy, and radiotherapy, can also induce antitumor immunity, thereby having cancer vaccine effects. (bmj.com)
  • Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation," Journal of Clinical Oncology , vol. 27, no. 35, pp. 5911-5918, 2009. (hindawi.com)
  • Dr Reiner Laus, president of the drug company, said the vaccine would have far milder side effects than existing treatments like chemotherapy and would hopefully be licensed by 2015. (telegraph.co.uk)
  • Efforts are underway to develop vaccines against that same protein. (healthline.com)
  • With the start of human testing, PsiOxus joins a competition with companies including Amgen Inc. (AMGN) , Jennerex Inc. and Transgene SA (TNG) to develop vaccines using oncolytic tumor viruses, pathogens that infect and destroy cancer cells. (bloomberg.com)
  • Breast Cancer We may have studies for Stage I, II, III, and IV breast cancer patients. (washington.edu)
  • The HER2/neu, the mutant protein most commonly found in breast cancer, led to drugs like trastuzumab ," said Faries. (healthline.com)
  • Drugs or physical treatments can mitigate the immunosuppressive cancer microenvironment and include chemotherapeutics, radiation, indoleamine 2,3-dioxygenase (IDO) inhibitors, inhibitors of T cell checkpoints, agonists of selected TNF receptor family members, and inhibitors of undesirable cytokines. (jci.org)
  • The conference will also aim to provide solutions to circumvent the challenges which face the development of successful targeted cancer treatments, within a competitive and important market. (smi-online.co.uk)
  • The 16+ industry led presentations and focus on the latest advances in personalised cancer treatments make this a leading event for the cancer vaccines industry. (smi-online.co.uk)
  • These vaccines might eventually help to stop further growth of the cancer, prevent a cancer from coming back and destroy cancer cells left behind after other treatments. (cancer.ca)
  • The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. (eurekalert.org)
  • If either the cancer treatment or a medicine the Abingdon, England-based company is developing for cachexia, a muscle- wasting and weight-loss condition, progress toward regulatory approval they could help PsiOxus generate revenue to fund other treatments still in the laboratory or lead to its sale. (bloomberg.com)
  • Vaccine is a biological preparation administered to produce acquired immunity in patients as well as healthy individuals. (openpr.com)
  • This only works in developing vaccines against viruses. (medicalnewstoday.com)
  • PsiOxus Therapeutics Ltd. began human testing of an experimental treatment that uses viruses to attack cancer cells while sparing healthy ones. (bloomberg.com)
  • There is "very little concrete evidence" that oncolytic viruses are effective in people, said Christian Ottensmeier, a professor of experimental cancer medicine at the University of Southampton in Southampton, England , who has worked on other cancer vaccines. (bloomberg.com)
  • Dendritic cell vaccines are made from dendritic cells that are grown in a lab together with cancer cells. (cancer.ca)
  • C. Doehn, A. Richter, R. Theodor, W. Lehmacher, and D. Jocham, "Prolongation of progression-free and overall survival following an adjuvant vaccination with Reniale in patients with non-metastatic renal cell carcinoma: secondary analysis of a multicenter phase-III trial [abstract]," in Proceedings of the 27th German Cancer Congress Program and Abstracts , vol. 395, 2006. (hindawi.com)
  • The research team, including co-principal investigator Dr. Pramod Srivastava of the Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut (UConn), publish their findings in the Journal of Experimental Medicine . (medicalnewstoday.com)
  • These vaccines are made to recognize proteins on certain cancer cells. (cancer.ca)
  • According to Science Daily , as cancer cells divide, they accumulate random DNA mutations (structural changes of a gene), some of which create mutated versions of proteins. (uconn.edu)
  • The most deadly form of brain cancer may be treatable with a vaccine that uses proteins from patients' own tumours, an encouraging preliminary trial suggests. (newscientist.com)
  • He adds that the approach of injecting cancer proteins has also worked against kidney and skin cancers. (newscientist.com)
  • Scientists and research physicians are constantly gaining greater understanding about the way the immunesystem interacts with cancer. (washington.edu)
  • An international team of scientists has used DNA from healthy cells have been used to create a cancer vaccine to treat prostate tumours. (theconversation.com)
  • Their discovery, as revealed by this research, will help scientists to design better targeted vaccine strategies to treat cancer and infections. (genengnews.com)
  • Have scientists found an anti-cancer vaccine? (medicalnewstoday.com)
  • To produce the vaccine, the scientists turned to induced pluripotent stem cells (iPSCs), or stem cells that are generated from adult cells. (medicalnewstoday.com)
  • The cancer treatment was developed by scientists who began work at the University of Birmingham in 2001 and moved to the University of Oxford the next year. (bloomberg.com)
  • Human papillomavirus (HPV) vaccines protect against infection caused by certain types of HPV. (cancer.ca)
  • Cancer vaccines are not new and unlike traditional vaccines which protect against infection, they work by making the immune system attack tumours already in the body. (theconversation.com)
  • ColoAd1 is much more potent as a cancer-killing virus but it doesn't kill any of the normal cells," Beadle said. (bloomberg.com)
  • Some/many of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient. (wikipedia.org)
  • Some of these targets (called "neoepitopes") can then be used as personalized vaccines to elicit a protective T cell response that destroys the cancer. (uconn.edu)
  • When mutant protein fragments are recognized as foreign invaders by immune cells called T cells, this prompts them to attack and eliminate cancer cells. (uconn.edu)
  • He says that Parsa's team would need to provide substantial evidence that the protein vaccine has a bigger benefit. (newscientist.com)
  • Growing year on year, Cancer Vaccines 2017 returns to London to discuss key developments in the immuno oncology sphere. (smi-online.co.uk)
  • Cancer Biotherapy and Radiopharmaceuticals , published 10 times per online with open access options and in print, is under the editorial leadership of Co-Editors-in-Chief Donald J. Buchsbaum, PhD, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham, and Robert K. Oldham, MD, CAMC-Teay's Valley Cancer Center. (eurekalert.org)
  • This Funding Opportunity Announcement (FOA) encourages research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. (medworm.com)
  • This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare deli. (medworm.com)
  • Their research showed that blocking CTLA-4 maintains the response of T cells triggered by the vaccines to attack the cancer. (innovations-report.com)
  • New research published in the journal Genome Medicine provides insights into the challenges of developing such a comprehensive cancer vaccine. (healthline.com)
  • This research has the potential to dramatically change how we treat cancer in the years to come. (uconn.edu)
  • The approval is for a subset of kidney cancer patients who are at intermediate risk for disease recurrence. (wikipedia.org)
  • By directing the immune system toward a specific target, a vaccine may prevent recurrence. (healthline.com)
  • The optimal time for boys and girls to receive the vaccine is at age 11 or 12, when studies have shown that their bodies produce the strongest antibody response. (theatlantic.com)
  • In studies in mice, Allison and his colleagues identified an antibody that blocks CTLA-4 and showed that it enhances the cancer-fighting activity of certain anti-cancer vaccines. (innovations-report.com)
  • The latter can alleviate immunosuppressive mechanisms in the cancer microenvironment and boost vaccine performance by appropriate stimulation or modulation of the immune system. (jci.org)
  • Other cancers are to some extent caused by bacterial infections (e.g. stomach cancer and Helicobacter pylori ). (wikipedia.org)
  • Therapeutic vaccination against established diseases such as persistent infections and cancer has proven much more challenging, because the vaccine intervention must combat an immune system that has been restrained by tolerizing or polarizing mechanisms that sustain the disease in a misguided attempt at self-tolerance. (jci.org)
  • Most vaccines help protect us from infections, such as measles or polio. (cancer.ca)
  • Oklahoma pediatrician Paul Darden wrote in the journal Pediatrics recently, "Despite doctors increasingly recommending adolescent vaccines, parents increasingly intend not to vaccinate female teens with [the] HPV [vaccine]. (theatlantic.com)